4. REFERENCES
1.Radmayr, C., et al. EAU Guidelines on Paediatric Urology. In: EAU Guidelines, edition presented at the annual EAU Congress Milan 2023. ISBN 978-94-92671-19-6.
https://pubmed.ncbi.nlm.nih.gov/25477258/
2.Blok, B., et al. EAU Guidelines on Neuro-urology. In: EAU Guidelines, edition presented at the annual EAU Congress Milan 2023. ISBN 978-94-92671-19-6.
https://uroweb.org/guideline/neuro-urology/
3.Guyatt, G.H., et al. What is “quality of evidence” and why is it important to clinicians? BMJ, 2008. 336: 995.
https://pubmed.ncbi.nlm.nih.gov/18456631/
4.Phillips B, et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998.
https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
5.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.
https://pubmed.ncbi.nlm.nih.gov/18467413/
6.Horan, T.C., et al. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control, 2008. 36: 309.
https://pubmed.ncbi.nlm.nih.gov/18538699/
7.Rubin, R.H., et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis, 1992. 15 Suppl 1: S216.
https://pubmed.ncbi.nlm.nih.gov/1477233/
8.Rubin, R.H., et al. General guidelines for the evaluation of new anti-infective drugs for the treatment of urinary tract infection. Eur Soc Clin Microbiol Infect Dis. Taukirchen, Germany., 1993: 240. [No abstract available].
9.U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry Uncomplicated Urinary Tract Infections — Developing Antimicrobial Drugs for Treatment. 2015.
https://www.fda.gov/media/129531/download
10.U.S. Department of Health and Human Services, F.a.D.A., Center for Drug Evaluation and Research (CDER). Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry 2018.
11.Johansen, T.E., et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int J Antimicrob Agents, 2011. 38 Suppl: 64.
https://pubmed.ncbi.nlm.nih.gov/22018988/
12.Singer, M., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016. 315: 801.
https://pubmed.ncbi.nlm.nih.gov/26903338/
13.Bell, B.G., et al. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis, 2014. 14: 13.
https://pubmed.ncbi.nlm.nih.gov/24405683/
14.WHO. Antimicrobial resistance: global report on surveillance 2014.
https://www.who.int/publications/i/item/9789241564748
15.Hulscher, M.E., et al. Antibiotic prescribing in hospitals: a social and behavioural scientific approach. Lancet Infect Dis, 2010. 10: 167.
https://pubmed.ncbi.nlm.nih.gov/20185095/
16.Goff, D.A., et al. A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. Lancet Infect Dis, 2017. 17: e56.
https://pubmed.ncbi.nlm.nih.gov/27866945/
17.Dellit, T.H., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis, 2007. 44: 159.
https://pubmed.ncbi.nlm.nih.gov/17173212/
18.Davey, P., et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev, 2017. 2: CD003543.
https://pubmed.ncbi.nlm.nih.gov/28178770/
19.Cefai, C., et al. Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use. NICE Guidelines, 2015.
https://www.nice.org.uk/guidance/ng15
20.Schuts, E.C., et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis, 2016. 16: 847.
https://pubmed.ncbi.nlm.nih.gov/26947617/
21.Hermanides, H.S., et al. Development of quality indicators for the antibiotic treatment of complicated urinary tract infections: a first step to measure and improve care. Clin Infect Dis, 2008. 46: 703.
https://pubmed.ncbi.nlm.nih.gov/18230045/
22.Spoorenberg, V., et al. Appropriate antibiotic use for patients with urinary tract infections reduces length of hospital stay. Clin Infect Dis, 2014. 58: 164.
https://pubmed.ncbi.nlm.nih.gov/24158412/
23.Lutay, N., et al. Bacterial control of host gene expression through RNA polymerase II. J Clin Invest, 2013. 123: 2366.
https://pubmed.ncbi.nlm.nih.gov/23728172/
24.Hansson, S., et al. Untreated asymptomatic bacteriuria in girls: II--Effect of phenoxymethylpenicillin and erythromycin given for intercurrent infections. BMJ, 1989. 298: 856.
https://pubmed.ncbi.nlm.nih.gov/2497823
25.Cai, T., et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: To treat or not to treat? Clin Infect Dis, 2012. 55: 771.
https://pubmed.ncbi.nlm.nih.gov/22677710/
26.Nicolle, L.E., et al. Infectious diseases society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis, 2005. 40: 643.
https://pubmed.ncbi.nlm.nih.gov/15714408/
27.Kass, E.H. Asymptomatic infections of the urinary tract. Trans Assoc Am Physicians, 1956. 69: 56.
https://pubmed.ncbi.nlm.nih.gov/13380946/
28.Gleckman, R., et al. Reliability of a single urine culture in establishing diagnosis of asymptomatic bacteriuria in adult males. J Clin Microbiol, 1979. 9: 596.
https://pubmed.ncbi.nlm.nih.gov/383746/
29.Warren, J.W., et al. A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis, 1982. 146: 719.
https://pubmed.ncbi.nlm.nih.gov/6815281/
30.Kunin CM. Urinary tract infections: detection, prevention and management. 5th ed. Baltimore: Williams and Wilkins., 1997.
31.Koves, B., et al. Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. Eur Urol, 2017.
https://pubmed.ncbi.nlm.nih.gov/28754533/
32.Tencer, J. Asymptomatic bacteriuria--a long-term study. Scand J Urol Nephrol, 1988. 22: 31.
https://pubmed.ncbi.nlm.nih.gov/3387908/
33.Asscher, A.W., et al. The clinical significance of asymptomatic bacteriuria in the nonpregnant woman. J Infect Dis, 1969. 120: 17.
https://pubmed.ncbi.nlm.nih.gov/5803281/
34.Elder, H.A., et al. The natural history of asymptomatic bacteriuria during pregnancy: the effect of tetracycline on the clinical course and the outcome of pregnancy. Am J Obstet Gynecol, 1971. 111: 441.
https://pubmed.ncbi.nlm.nih.gov/4937729/
35.Elder, H.A., et al. Use of sulfasymazine in the treatment of bacteriuria of pregnancy. Antimicrob Agents Chemother (Bethesda), 1966. 6: 142.
https://pubmed.ncbi.nlm.nih.gov/4862162/
36.Gold, E.M., et al. Asymptomatic bacteriuria during pregnancy. Obstet Gynecol, 1966. 27: 206.
https://pubmed.ncbi.nlm.nih.gov/5325600/
37.Kass, E.H. Pyelonephritis and bacteriuria. A major problem in preventive medicine. Ann Intern Med, 1962. 56: 46.
https://pubmed.ncbi.nlm.nih.gov/14454174/
38.Kincaid-Smith, P., et al. Bacteriuria in Pregnancy. Lancet, 1965. 1: 395.
https://pubmed.ncbi.nlm.nih.gov/14238090/
39.Little, P.J. The incidence of urinary infection in 5000 pregnant women. Lancet, 1966. 2: 925.
https://pubmed.ncbi.nlm.nih.gov/4162367/
40.Mulla, N. Bacteriuria in pregnancy. Obstet Gynecol, 1960. 16: 89.
https://pubmed.ncbi.nlm.nih.gov/14425118/
41.Pathak, U.N., et al. Bacteriuria of pregnancy: results of treatment. J Infect Dis, 1969. 120: 91.
https://pubmed.ncbi.nlm.nih.gov/5816817/
42.Robertson, J.G., et al. The managment and complications of asymptomatic bacteriuria in pregnancy. Report of a study on 8,275 patients. J Obstet Gynaecol Br Commonw, 1968. 75: 59.
https://pubmed.ncbi.nlm.nih.gov/5635245/
43.Thomsen, A.C., et al. Antibiotic elimination of group-B streptococci in urine in prevention of preterm labour. Lancet, 1987. 1: 591.
https://pubmed.ncbi.nlm.nih.gov/2881132/
44.Williams, G.L., et al. Urinary concentrating ability in women with asymptomatic bacteriuria in pregnancy. Br Med J, 1969. 3: 212.
https://pubmed.ncbi.nlm.nih.gov/5792611/
45.Wren, B.G. Subclinical renal infection and prematurity. Med J Aust, 1969. 2: 596.
https://pubmed.ncbi.nlm.nih.gov/5388374/
46.Kazemier, B.M., et al. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial. Lancet Infect Dis, 2015. 15: 1324.
https://pubmed.ncbi.nlm.nih.gov/26255208/
47.Christopher, L.J., et al. A trial of hippramine in the treatment of bacteriuria of pregnancy. Ir J Med Sci, 1969. 8: 331.
https://pubmed.ncbi.nlm.nih.gov/5806178/
48.Reeves, D.S. Laboratory and clinical studies with sulfametopyrazine as a treatment for bacteriuria in pregnancy. J Antimicrob Chemother, 1975. 1: 171.
https://pubmed.ncbi.nlm.nih.gov/1100589/
49.Whalley, P.J., et al. Short-term versus continuous antimicrobial therapy for asymptomatic bacteriuria in pregnancy. Obstet Gynecol, 1977. 49: 262.
https://pubmed.ncbi.nlm.nih.gov/320525/
50.Bint, A., et al. A comparative trial of pivmecillinam and ampicillin in bacteriuria of pregnancy. Infection, 1979. 7: 290.
https://pubmed.ncbi.nlm.nih.gov/232697/
51.Harris, R.E., et al. Single-dose antimicrobial therapy for asymptomatic bacteriuria during pregnancy. Obstet Gynecol, 1982. 59: 546.
https://pubmed.ncbi.nlm.nih.gov/7070725/
52.Bailey, R.R., et al. Comparison of single dose with a 5-day course of co-trimoxazole for asymptomatic (covert) bacteriuria of pregnancy. Aust N Z J Obstet Gynaecol, 1983. 23: 139.
https://pubmed.ncbi.nlm.nih.gov/6606421/
53.Masterton, R.G., et al. Single-dose amoxycillin in the treatment of bacteriuria in pregnancy and the puerperium--a controlled clinical trial. Br J Obstet Gynaecol, 1985. 92: 498.
https://pubmed.ncbi.nlm.nih.gov/3888250/
54.Pedler, S.J., et al. Comparative study of amoxicillin-clavulanic acid and cephalexin in the treatment of bacteriuria during pregnancy. Antimicrob Agents Chemother, 1985. 27: 508.
https://pubmed.ncbi.nlm.nih.gov/4004191/
55.Campbell-Brown, M., et al. Is screening for bacteriuria in pregnancy worth while? Br Med J (Clin Res Ed), 1987. 294: 1579.
https://pubmed.ncbi.nlm.nih.gov/3113538/
56.Pregazzi, R., et al. [Single-dose antibiotic therapy of asymptomatic bacteriuria in pregnancy. Results and complications]. Minerva Ginecol, 1987. 39: 289.
https://pubmed.ncbi.nlm.nih.gov/3601207/
57.Gerstner, G.J., et al. Amoxicillin in the treatment of asymptomatic bacteriuria in pregnancy: a single dose of 3 g amoxicillin versus a 4-day course of 3 doses 750 mg amoxicillin. Gynecol Obstet Invest, 1989. 27: 84.
https://pubmed.ncbi.nlm.nih.gov/2659442/
58.Olsen, L., et al. Single-dose versus six-day therapy with sulfamethizole for asymptomatic bacteriuria during pregnancy. A prospective randomised study. Dan Med Bull, 1989. 36: 486.
https://pubmed.ncbi.nlm.nih.gov/2680315/
59.Thoumsin, H., et al. Single dose fosfomycin trometamol versus multiple dose nitrofurantoin in pregnant women with bacteriuria: preliminary results. Infection, 1990. 18 Suppl 2: S94.
https://pubmed.ncbi.nlm.nih.gov/2286469/
60.Bayrak, O., et al. Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimester of pregnancy? Int Urogynecol J Pelvic Floor Dysf, 2007. 18: 525.
https://pubmed.ncbi.nlm.nih.gov/16941068/
61.Estebanez, A., et al. Fosfomycin in a single dose versus a 7-day course of amoxicillin- clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. Eur J Clin Microbiol Infect Dis, 2009. 28: 1457.
https://pubmed.ncbi.nlm.nih.gov/19768649/
62.Lumbiganon, P., et al. One-day compared with 7-day nitrofurantoin for asymptomatic bacteriuria in pregnancy: A randomized controlled trial. Obstet Gynecol, 2009. 113: 339.
https://pubmed.ncbi.nlm.nih.gov/19155904/
63.Widmer, M., et al. Duration of treatment for asymptomatic bacteriuria during pregnancy. Cochrane Database Syst Rev, 2015: CD000491.
https://pubmed.ncbi.nlm.nih.gov/26560337/
64.Zhanel, G.G., et al. Asymptomatic bacteriuria in patients with diabetes mellitus. Rev Infect Dis, 1991. 13: 150.
https://pubmed.ncbi.nlm.nih.gov/2017615/
65.Harding, G.K., et al. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med, 2002. 347: 1576.
https://pubmed.ncbi.nlm.nih.gov/12432044/
66.Mody, L., et al. Urinary tract infections in older women: a clinical review. JAMA, 2014. 311: 844.
https://pubmed.ncbi.nlm.nih.gov/24570248/
67.Boscia, J.A., et al. Therapy vs no therapy for bacteriuria in elderly ambulatory nonhospitalized women. JAMA, 1987. 257: 1067.
https://pubmed.ncbi.nlm.nih.gov/3806896/
68.Abrutyn, E., et al. Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women? Ann Intern Med, 1994. 120: 827.
https://pubmed.ncbi.nlm.nih.gov/7818631/
69.Abrutyn, E., et al. Does treatment of asymptomatic bacteriuria in older ambulatory women reduce subsequent symptoms of urinary tract infection? J Am Geriatr Soc, 1996. 44: 293.
https://pubmed.ncbi.nlm.nih.gov/8600199/
70.Nicolle, L.E., et al. Prospective randomized comparison of therapy and no therapy for asymptomatic bacteriuria in institutionalized elderly women. Am J Med, 1987. 83: 27.
https://pubmed.ncbi.nlm.nih.gov/3300325/
71.Nicolle, L.E. Asymptomatic bacteriuria in the elderly. Infect Dis Clin North Am, 1997. 11: 647.
https://pubmed.ncbi.nlm.nih.gov/9378928/
72.Silver, S.A., et al. Positive urine cultures: A major cause of inappropriate antimicrobial use in hospitals? Can
J Infect Dis Med Microbiol, 2009. 20: 107.
https://pubmed.ncbi.nlm.nih.gov/21119801/
73.Trautner, B.W. Asymptomatic bacteriuria: when the treatment is worse than the disease. Nat Rev Urol, 2011.
https://pubmed.ncbi.nlm.nih.gov/22143416/
74.Nicolle, L.E., et al. Bacteriuria in elderly institutionalized men. N Engl J Med, 1983. 309: 1420.
https://pubmed.ncbi.nlm.nih.gov/6633618/
75.Potts, L., et al. A double-blind comparative study of norfloxacin versus placebo in hospitalised elderly patients with asymptomatic bacteriuria. Arch Gerontol Geriatr, 1996. 23: 153.
https://pubmed.ncbi.nlm.nih.gov/15374159/
76.Renneberg, J., et al. Single-day treatment with trimethoprim for asymptomatic bacteriuria in the elderly patient.
J Urol, 1984. 132: 934.
https://pubmed.ncbi.nlm.nih.gov/6387184/
77.Ouslander, J.G., et al. Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents? Ann Intern Med, 1995. 122: 749.
https://pubmed.ncbi.nlm.nih.gov/7717597/
78.Moradi, M., et al. Effect of antibiotic therapy on asymptomatic bacteriuria in kidney transplant recipients. Urol J, 2005. 2: 32.
https://pubmed.ncbi.nlm.nih.gov/17629893/
79.Amari, E.B.E., et al. Outcome of treated and untreated asymptomatic bacteriuria in renal transplant recipients. Nephrol Dialysis Transpl, 2011. 26: 4109.
https://pubmed.ncbi.nlm.nih.gov/21592976/
80.Green, H., et al. Consequences of treated versus untreated asymptomatic bacteriuria in the first year following kidney transplantation: Retrospective observational study. Eur J Clin Microbiol Infect Dis, 2013. 32: 127.
https://pubmed.ncbi.nlm.nih.gov/22918514/
81.Origuen, J., et al. Should asymptomatic bacteriuria be systematically treated in kidney transplant recipients? Results from a randomized controlled trial. Am J Transplant, 2016.
https://pubmed.ncbi.nlm.nih.gov/27088545/
82.Nicolle, L.E. Urinary tract infections in patients with spinal injuries. Curr Infect Dis Rep, 2014. 16: 390.
https://pubmed.ncbi.nlm.nih.gov/24445675/
83.Wullt, B., et al. Bladder, bowel and bugs--bacteriuria in patients with intestinal urinary diversion. World J Urol, 2004. 22: 186.
https://pubmed.ncbi.nlm.nih.gov/15309491/
84.Darouiche, R.O., et al. Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial. Clin Infect Dis, 2005. 41: 1531.
https://pubmed.ncbi.nlm.nih.gov/16231269/
85.Sunden, F., et al. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J Urol, 2010. 184: 179.
https://pubmed.ncbi.nlm.nih.gov/20483149/
86.Bonkat, G., et al. Microbial biofilm formation and catheter-associated bacteriuria in patients with suprapubic catheterisation. World J Urol, 2013. 31: 565.
https://pubmed.ncbi.nlm.nih.gov/22926265/
87.Tenke, P., et al. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents, 2008. 31 Suppl 1: S68.
https://pubmed.ncbi.nlm.nih.gov/18006279/
88.Cooper, F.P., et al. Policies for replacing long-term indwelling urinary catheters in adults. Cochrane Database Syst Rev, 2016. 7: CD011115.
https://pubmed.ncbi.nlm.nih.gov/27457774/
89.Dasgupta, R., et al. Preoperative antibiotics before endourologic surgery: current recommendations. J Endourol, 2009. 23: 1567.
https://pubmed.ncbi.nlm.nih.gov/19785548/
90.Sobel, J.D., et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis, 2000. 30: 19.
https://pubmed.ncbi.nlm.nih.gov/10619727/
91.Grabe, M., et al. The effect of a short antibiotic course in transurethral prostatic resection. Scand J Urol Nephrol, 1984. 18: 37.
https://pubmed.ncbi.nlm.nih.gov/6202000/
92.Grabe, M., et al. Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery. Eur J Clin Microbiol, 1987. 6: 11.
https://pubmed.ncbi.nlm.nih.gov/3569248/
93.Cafferkey, M.T., et al. Antibiotics for the prevention of septicaemia in urology. J Antimicrob Chemother, 1982.
9: 471.
https://pubmed.ncbi.nlm.nih.gov/7107549/
94.Murphy, D.M., et al. Bacteraemia during prostatectomy and other transurethral operations: influence of timing of antibiotic administration. J Clin Pathol, 1984. 37: 673.
https://pubmed.ncbi.nlm.nih.gov/6725613/
95.Chong, J.T., et al. Pre-procedural antibiotics for endoscopic urological procedures: Initial experience in individuals with spinal cord injury and asymptomatic bacteriuria. J Spinal Cord Med, 2015. 38: 187.
https://pubmed.ncbi.nlm.nih.gov/24621035/
96.Cordero-Ampuero, J., et al. Are antibiotics necessary in hip arthroplasty with asymptomatic bacteriuria? Seeding risk with/without treatment. Clin Orthopaed Rel Res, 2013. 471: 3822.
https://pubmed.ncbi.nlm.nih.gov/23430723/
97.Sousa, R., et al. Is asymptomatic bacteriuria a risk factor for prosthetic joint infection? Clin Infect Dis, 2014. 59: 41.
https://pubmed.ncbi.nlm.nih.gov/24723280/
98.Foxman, B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon, 2003. 49: 53.
https://pubmed.ncbi.nlm.nih.gov/12601337/
99.Wagenlehner, F.M., et al. Uncomplicated urinary tract infections. Dtsch Arztebl Int, 2011. 108: 415.
https://pubmed.ncbi.nlm.nih.gov/21776311/
100.Stamm, W.E., et al. Management of urinary tract infections in adults. N Engl J Med, 1993. 329: 1328.
https://pubmed.ncbi.nlm.nih.gov/8413414/
101.Foxman, B., et al. Urinary tract infection among women aged 40 to 65: behavioral and sexual risk factors. J Clin Epidemiol, 2001. 54: 710.
https://pubmed.ncbi.nlm.nih.gov/11438412/
102.van Buul, L.W., et al. The Development of a Decision Tool for the Empiric Treatment of Suspected Urinary Tract Infection in Frail Older Adults: A Delphi Consensus Procedure. J Am Med Dir Assoc, 2018. 19: 757.
https://pubmed.ncbi.nlm.nih.gov/29910137/
103.Bent, S., et al. Does this woman have an acute uncomplicated urinary tract infection? JAMA, 2002. 287: 2701.
https://pubmed.ncbi.nlm.nih.gov/12020306/
104.Bradbury, S.M. Collection of urine specimens in general practice: to clean or not to clean? J R Coll Gen Pract, 1988. 38: 363.
https://pubmed.ncbi.nlm.nih.gov/3256648/
105.Lifshitz, E., et al. Outpatient urine culture: does collection technique matter? Arch Intern Med, 2000. 160: 2537.
https://pubmed.ncbi.nlm.nih.gov/10979067/
106.Fihn, S.D. Clinical practice. Acute uncomplicated urinary tract infection in women. N Engl J Med, 2003. 349: 259.
https://pubmed.ncbi.nlm.nih.gov/12867610/
107.Foxman, B., et al. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am, 2003. 17: 227.
https://pubmed.ncbi.nlm.nih.gov/12848468/
108.Falagas, M.E., et al. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials. J Infect, 2009. 58: 91.
https://pubmed.ncbi.nlm.nih.gov/19195714/
109.Gagyor, I., et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ, 2015. 351: h6544.
https://pubmed.ncbi.nlm.nih.gov/26698878/
110.Vik, I., et al. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial. PLoS Med, 2018. 15: e1002569.
https://pubmed.ncbi.nlm.nih.gov/29763434/
111.Kronenberg, A., et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ, 2017. 359: j4784.
https://pubmed.ncbi.nlm.nih.gov/29113968/
112.Wagenlehner, F.M., et al. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int, 2018. 101: 327.
https://pubmed.ncbi.nlm.nih.gov/30231252/
113.Gupta, K., et al. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med, 2007. 167: 2207.
https://pubmed.ncbi.nlm.nih.gov/17998493/
114.Lecomte, F., et al. Single-dose treatment of cystitis with fosfomycin trometamol (Monuril): analysis of 15 comparative trials on 2,048 patients. Giorn It Ost Gin, 1997. 19: 399.
https://www.sciencedirect.com/science/article/pii/S0399077X96802095
115.Nicolle, L.E. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother, 2000. 46 Suppl
1: 35.
https://pubmed.ncbi.nlm.nih.gov/11051622/
116.Huttner, A., et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother, 2015. 70: 2456.
https://pubmed.ncbi.nlm.nih.gov/26066581/
117.Gupta, K., et al. Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI. Int J Antimicrob Agents, 2002. 19: 554.
https://pubmed.ncbi.nlm.nih.gov/12135847/
118.Warren, J.W., et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis, 1999. 29: 745.
https://pubmed.ncbi.nlm.nih.gov/10589881/
119.Hooton, T.M., et al. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA, 2012. 307: 583.
https://pubmed.ncbi.nlm.nih.gov/22318279/
120.Hooton, T.M., et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. Jama, 2005. 293: 949.
https://pubmed.ncbi.nlm.nih.gov/15728165/
121.European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Quinolone and fluoroquinolone Article-31 referral, 2019.
122.Vazquez, J.C., et al. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database Syst Rev, 2000: CD002256.
https://pubmed.ncbi.nlm.nih.gov/10908537/
123.Wagenlehner, F.M., et al. Antimicrobials in urogenital infections. Int J Antimicrob Agents, 2011. 38 Suppl: 3.
https://pubmed.ncbi.nlm.nih.gov/22019184/
124.Geerts, A.F., et al. Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. Eur J Clin Pharmacol, 2013. 69: 1701.
https://pubmed.ncbi.nlm.nih.gov/23660771/
125.Hooton, T.M. Recurrent urinary tract infection in women. Int J Antimicrob Agents, 2001. 17: 259.
https://pubmed.ncbi.nlm.nih.gov/11295405/
126.Naber, K.G., et al. Psychosocial burden of recurrent uncomplicated urinary tract infections. GMS Infect Dis, 2022. 10: Doc01.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006425/
127.van Haarst, E.P., et al. Evaluation of the diagnostic workup in young women referred for recurrent lower urinary tract infections. Urology, 2001. 57: 1068.
https://pubmed.ncbi.nlm.nih.gov/11377307/
128.Hooton, T.M., Prevention of recurrent urogenital tract infections in adult women, in EAU/International Consultation on Urological Infections. T, K.G. Naber, A.J. Schaeffer, C.F. Hynes & e. al., Editors. 2010, European Association of Urology: The Netherlands.
129.Cai, T., et al. Management of Recurrent Cystitis in Women: When Prompt Identification of Risk Factors Might Make a Difference. Eur Urol Focus, 2022.
https://pubmed.ncbi.nlm.nih.gov/35135727/
130.Adatto, K., et al. Behavioral factors and urinary tract infection. JAMA, 1979. 241: 2525.
https://pubmed.ncbi.nlm.nih.gov/439337/
131.Lumsden, L., et al. Effects of an educational intervention on the rate of recurrent urinary tract infections in selected female outpatients. Women Health, 1985. 10: 79.
https://pubmed.ncbi.nlm.nih.gov/3984360/
132.Hooton, T.M., et al. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Intern Med, 2018. 178: 1509.
https://pubmed.ncbi.nlm.nih.gov/30285042/
133.Chen, Y.Y., et al. Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials. Int Urogynecol J, 2021. 32: 17.
https://pubmed.ncbi.nlm.nih.gov/32564121/
134.Beerepoot, M.A.J., et al. Nonantibiotic prophylaxis for recurrent urinary tract infections: A systematic review and meta-analysis of randomized controlled trials. J Urol, 2013. 190: 1981.
https://pubmed.ncbi.nlm.nih.gov/23867306
135.Leckie, K.J. What is the evidence for the role of oestrogen in the prevention of recurrent urinary tract infections in postmenopausal women? An evidence-based review. J Clin Gerontol Geriatr, 2010. 1: 31.
https://www.sciencedirect.com/science/article/pii/S2210833510000298?via%3Dihub
136.Duenas-Garcia, O.F., et al. Pharmacological agents to decrease new episodes of recurrent lower urinary tract infections in postmenopausal women. A systematic review. Female Pelvic Med Reconstruct Surg, 2016. 22: 63.
https://pubmed.ncbi.nlm.nih.gov/26825411/
137.Pinggera, G.M., et al. Effects of local estrogen therapy on recurrent urinary tract infections in young females under oral contraceptives. Eur Urol, 2005. 47: 243.
https://pubmed.ncbi.nlm.nih.gov/15661421/
138.Aziminia, N., et al. Vaccines for the prevention of recurrent urinary tract infections: a systematic review. BJU Int, 2019. 123: 753.
https://pubmed.ncbi.nlm.nih.gov/30378242/
139.Prattley, S., et al. Role of Vaccines for Recurrent Urinary Tract Infections: A Systematic Review. Eur Urol Focus, 2020. 6: 593.
https://pubmed.ncbi.nlm.nih.gov/31806578/
140.Naber, K.G., et al. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int
J Antimicrob Agents, 2009. 33: 111.
https://pubmed.ncbi.nlm.nih.gov/18963856/
141.Nickel, J.C., et al. Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future. Can Urol Assoc J, 2020. 14: 281.
https://pubmed.ncbi.nlm.nih.gov/33626320/
142.Lorenzo-Gómez, M. F., et al. Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections. NEJM Evidence, 2022. 1: EVIDoa2100018.
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2100018
143.Nestler, S., et al. Efficacy of vaccination with StroVac for recurrent urinary tract infections in women: a comparative single-centre study.Int Urol Nephrol, 2021. 53: 2267.
https://pubmed.ncbi.nlm.nih.gov/34499326/
144.Kranz, J., et al. Current Evidence on Nonantibiotic Prevention of Recurrent Urinary Tract Infections. Eur Urol Focus, 2019. 5: 17.
https://pubmed.ncbi.nlm.nih.gov/30292420/
145.Abad, C.L., et al. The role of Lactobacillus probiotics in the treatment or prevention of urogenital infections - A systematic review. J Chemother, 2009. 21: 243.
https://pubmed.ncbi.nlm.nih.gov/19567343/
146.Canales, J., et al. Are probiotics effective in preventing urinary tract infection? Medwave, 2018. 18: e7186.
https://pubmed.ncbi.nlm.nih.gov/29624569/
147.Falagas, M.E., et al. Probiotics for prevention of recurrent urinary tract infections in women: A review of the evidence from microbiological and clinical studies. Drugs, 2006. 66: 1253.
https://pubmed.ncbi.nlm.nih.gov/16827601/
148.Grin, P.M., et al. Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis. Can
J Urol, 2013. 20: 6607.
https://pubmed.ncbi.nlm.nih.gov/23433130/
149.Hanson, L., et al. Probiotics for Treatment and Prevention of Urogenital Infections in Women: A Systematic Review. J Midwife Women’s Health, 2016. 61: 339.
https://pubmed.ncbi.nlm.nih.gov/27218592/
150.Ng, Q.X., et al. Use of Lactobacillus spp. to prevent recurrent urinary tract infections in females. Medical Hypotheses, 2018. 114: 49.
https://pubmed.ncbi.nlm.nih.gov/29602464/
151.Akgul, T., et al. The role of probiotics in women with recurrent urinary tract infections. Turkish J Urol, 2018. 44: 377.
https://pubmed.ncbi.nlm.nih.gov/30487041/
152.Andreu, A. Lactobacillus as a probiotic for preventing urogenital infections. Rev Med Microbiol, 2004. 15: 1.
153.Barrons, R., et al. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: A review. Clin Ther, 2008. 30: 453.
https://pubmed.ncbi.nlm.nih.gov/18405785/
154.Hoesl, C.E., et al. The probiotic approach: An alternative treatment option in urology. Eur Urology, 2005. 47: 288.
https://pubmed.ncbi.nlm.nih.gov/15716188/
155.Ray, K. Infection: Lactobacillus probiotic could prevent recurrent UTI. Nat Rev Urol, 2011. 8: 292.
https://pubmed.ncbi.nlm.nih.gov/21660070/
156.Reid, G., et al. Probiotics to prevent urinary tract infections: The rationale and evidence. World J Urol, 2006. 24: 28.
https://pubmed.ncbi.nlm.nih.gov/16389539/
157.Abdullatif, V.A., et al. Efficacy of Probiotics as Prophylaxis for Urinary Tract Infections in Premenopausal Women: A Systematic Review and Meta-Analysis. Cureus, 2021. 13: e18843.
https://pubmed.ncbi.nlm.nih.gov/34671514/
158.Jepson, R.G., et al. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev, 2012.
10: CD001321.
https://pubmed.ncbi.nlm.nih.gov/23076891/
159.Fu, Z., et al. Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis. J Nutr, 2017. 147: 2282.
https://pubmed.ncbi.nlm.nih.gov/29046404/
160.Luis, A., et al. Can Cranberries Contribute to Reduce the Incidence of Urinary Tract Infections? A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Clinical Trials. J Urol, 2017. 198: 614.
https://pubmed.ncbi.nlm.nih.gov/28288837/
161.Wang, C.H., et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med, 2012.
172: 988.
https://pubmed.ncbi.nlm.nih.gov/22777630/
162.Tambunan, M.P., et al. Cranberries for women with recurrent urinary tract infection: A meta-analysis. Med
J Indonesia, 2019. 28: 268.
http://mji.ui.ac.id/journal/index.php/mji/article/view/3299/1579
163.Xia, J.Y., et al. Consumption of cranberry as adjuvant therapy for urinary tract infections in susceptible populations: A systematic review and meta-analysis with trial sequential analysis. PLoS ONE, 2021.
16: e0256992.
https://pubmed.ncbi.nlm.nih.gov/34473789/
164.Liska, D.J., et al. Cranberries and Urinary Tract Infections: How Can the Same Evidence Lead to Conflicting Advice? Adv Nutr, 2016. 7: 498.
https://pubmed.ncbi.nlm.nih.gov/27184277/
165.Babar, A., et al. High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial. BMC Urol, 2021. 21: 44.
https://pubmed.ncbi.nlm.nih.gov/33757474/
166.Lenger, S.M., et al. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology, 2020. 223: 265.
https://pubmed.ncbi.nlm.nih.gov/32497610/
167.Kyriakides, R., et al. Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature. Eur Urol Focus, 2021. 7: 1166.
https://pubmed.ncbi.nlm.nih.gov/32972899/
168.Cooper, T.E., et al. D-mannose for preventing and treating urinary tract infections. Cochrane Database Syst Rev, 2022. 8: CD013608.
https://pubmed.ncbi.nlm.nih.gov/36041061/
169.Damiano, R., et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol, 2011. 59: 645.
https://pubmed.ncbi.nlm.nih.gov/21272992/
170.De Vita, D., et al. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis:
A randomized study. Int Urogynecol J, 2012. 23: 1707.
https://pubmed.ncbi.nlm.nih.gov/22614285/
171.Goddard, J.C., et al. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis. Int Urogynecol J, 2018. 29: 933.
https://pubmed.ncbi.nlm.nih.gov/29181550/
172.Lee, B.S., et al. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev, 2012. 10: CD003265.
https://pubmed.ncbi.nlm.nih.gov/23076896/
173.Bakhit, M., et al. Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis. Br J Gen Pract, 2021. 71: e528.
https://pubmed.ncbi.nlm.nih.gov/34001538/
174.Harding, C., et al. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT. Health Technol Assess, 2022. 26: 1.
https://pubmed.ncbi.nlm.nih.gov/35535708/
175.Harding, C., et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ, 2022. 376: e068229.
https://pubmed.ncbi.nlm.nih.gov/35264408/
176.Nalliah, S., et al. The use of chemotherapeutic agents as prophylaxis for recurrent urinary tract infection in healthy nonpregnant women: A network meta-Analysis. Indian J Urol, 2019. 35: 147.
https://pubmed.ncbi.nlm.nih.gov/31000921/
177.Ahmed, H., et al. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: Systematic review and meta-analysis of randomised trials. BMJ Open, 2017. 7: e015233.
https://pubmed.ncbi.nlm.nih.gov/28554926/
178.Price, J.R., et al. Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol, 2016. 215: 548.
https://pubmed.ncbi.nlm.nih.gov/27457111/
179.Albert, X., et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev (Online), 2004: CD001209.
https://pubmed.ncbi.nlm.nih.gov/15266443/
180.Eells, S.J., et al. Recurrent urinary tract infections among women: Comparative effectiveness of 5 prevention and management strategies using a markov chain monte carlo model. Clin Infect Dis, 2014. 58: 147.
https://pubmed.ncbi.nlm.nih.gov/24065333/
181.Anger, J., et al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J Urol, 2019. 202: 282.
https://pubmed.ncbi.nlm.nih.gov/31042112/
182.Kranz, J., et al. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. Urol Int, 2018. 100: 271.
https://pubmed.ncbi.nlm.nih.gov/29539622/
183.Epp, A., et al. No. 250-Recurrent Urinary Tract Infection. J Obstet Gynaecol Canada, 2017. 39: e422.
https://pubmed.ncbi.nlm.nih.gov/28935065/
184.Lichtenberger, P., et al. Antimicrobial prophylaxis in women with recurrent urinary tract infections. Int J Antimicrob Agents, 2011. 38: 36.
https://pubmed.ncbi.nlm.nih.gov/22055655/
185.Sen, A. Recurrent cystitis in non-pregnant women. BMJ Clin Evid, 2008. 2008.
https://pubmed.ncbi.nlm.nih.gov/19445741/
186.Chew, L.D., et al. Recurrent cystitis in nonpregnant women. Western J Med, 1999. 170: 274.
https://pubmed.ncbi.nlm.nih.gov/10379218/
187.Rudenko, N., et al. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol: Double blind, randomized, parallel group, placebo controlled study. Arzneimittel-Forschung/Drug Research, 2005. 55: 420.
https://pubmed.ncbi.nlm.nih.gov/16080282/
188.Pfau, A., et al. Effective prophylaxis for recurrent urinary tract infections during pregnancy. Clin Infect Dis, 1992. 14: 810.
https://pubmed.ncbi.nlm.nih.gov/1576275/
189.Schaeffer, A.J., et al. Efficacy and safety of self-start therapy in women with recurrent urinary tract infections.
J Urol, 1999. 161: 207.
https://pubmed.ncbi.nlm.nih.gov/10037399/
190.Scholes, D., et al. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med, 2005. 142: 20.
https://pubmed.ncbi.nlm.nih.gov/15630106/
191.Hill, J.B., et al. Acute pyelonephritis in pregnancy. Obstet Gynecol, 2005. 105: 18.
https://pubmed.ncbi.nlm.nih.gov/15625136/
192.Fulop, T. Acute Pyelonephritis Workup. 2012.
https://emedicine.medscape.com/article/245559-workup
193.van Nieuwkoop, C., et al. Predicting the need for radiologic imaging in adults with febrile urinary tract infection. Clin Infect Dis, 2010. 51: 1266.
https://pubmed.ncbi.nlm.nih.gov/21034195/
194.Cattrall, J.W.S., et al. A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis, 2018. 37: 2285.
https://pubmed.ncbi.nlm.nih.gov/30191339/
195.Gupta, K., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis, 2011. 52: e103.
https://pubmed.ncbi.nlm.nih.gov/21292654/
196.Berti, F., et al. Short versus long course antibiotic therapy for acute pyelonephritis in adults: A systematic review and meta-analysis. Italian J Med, 2018. 12: 39.
https://www.italjmed.org/index.php/ijm/article/view/itjm.2018.840/1079
197.Hooton, T.M. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med, 2012. 366: 1028.
https://pubmed.ncbi.nlm.nih.gov/22417256/
198.Arakawa, S., et al. The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection. J Infect Chemother, 2019. 25: 104.
https://pubmed.ncbi.nlm.nih.gov/30420153/
199.Armstrong, E.S., et al. Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections. BMC Infect Dis, 2016. 16: 710.
https://pubmed.ncbi.nlm.nih.gov/27887579/
200.Huntington, J.A., et al. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacinresistant pathogens: Results from the ASPECT-cUTI trial.
J Antimicrob Chemother, 2016. 71: 2014.
https://pubmed.ncbi.nlm.nih.gov/26994090/
201.Carmeli, Y., et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis, 2016.
16: 661.
https://pubmed.ncbi.nlm.nih.gov/27107460/
202.Sims, M., et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother, 2017. 72: 2616.
https://pubmed.ncbi.nlm.nih.gov/28575389/
203.Wagenlehner, F.M., et al. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis, 2016. 63: 754.
https://pubmed.ncbi.nlm.nih.gov/27313268/
204.Kaye, K.S., et al. Effect of meropenem-vaborbactam vs piperacillin-Tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection the TANGO I randomized clinical trial. JAMA, 2018. 319: 788.
https://pubmed.ncbi.nlm.nih.gov/29486041/
205.Wunderink, R.G., et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther, 2018. 7: 439.
https://pubmed.ncbi.nlm.nih.gov/30270406/
206.Wagenlehner, F.M.E., et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med, 2019. 380: 729.
https://pubmed.ncbi.nlm.nih.gov/30786187/
207.Portsmouth, S., et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis, 2018. 18: 1319.
https://pubmed.ncbi.nlm.nih.gov/30509675/
208.Pitout, J.D. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs, 2010. 70: 313.
https://pubmed.ncbi.nlm.nih.gov/20166768/
209.Mombelli, G., et al. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med, 1999. 159: 53.
https://pubmed.ncbi.nlm.nih.gov/9892331/
210.Millar, L.K., et al. Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial. Obstet Gynecol, 1995. 86: 560.
https://pubmed.ncbi.nlm.nih.gov/7675380/
211.Wing, D.A., et al. A randomized trial of three antibiotic regimens for the treatment of pyelonephritis in pregnancy. Obstet Gynecol, 1998. 92: 249.
https://pubmed.ncbi.nlm.nih.gov/9699761/
212.Ulleryd, P., et al. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis, 2003. 35: 34.
https://pubmed.ncbi.nlm.nih.gov/12685882/
213.Reyner, K., et al. Urinary obstruction is an important complicating factor in patients with septic shock due to urinary infection. Am J Emerg Med, 2016. 34: 694.
https://pubmed.ncbi.nlm.nih.gov/26905806/
214.Heyns, C.F. Urinary tract infection associated with conditions causing urinary tract obstruction and stasis, excluding urolithiasis and neuropathic bladder. World J Urol, 2012. 30: 77.
https://pubmed.ncbi.nlm.nih.gov/21720861/
215.Spoorenberg, V., et al. [Better antibiotic use in complicated urinary tract infections; multicentre cluster randomised trial of 2 improvement strategies]. Ned Tijdschr Geneeskd, 2016. 160: D460.
https://pubmed.ncbi.nlm.nih.gov/27438395/
216.Bader, M.S., et al. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med, 2017. 129: 242.
https://pubmed.ncbi.nlm.nih.gov/27712137/
217.Geerlings, S.E., et al. SWAB Guidelines for Antimicrobial Therapy of Complicated Urinary Tract Infections in Adults. SWAB Guidelines, 2013.
https://pubmed.ncbi.nlm.nih.gov/17100128/
218.Hooton, T.M., et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis, 2010. 50: 625.
https://pubmed.ncbi.nlm.nih.gov/20175247/
219.Peterson, J., et al. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006. Clin Ther, 2007. 29: 2215.
https://pubmed.ncbi.nlm.nih.gov/18042477/
220.Bader, M.S., et al. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med, 2010. 122: 7.
https://pubmed.ncbi.nlm.nih.gov/21084776/
221.Wagenlehner, F., et al. The Global Prevalence of Infections in Urology Study: A Long-Term, Worldwide Surveillance Study on Urological Infections. Pathogens, 2016. 5.
https://pubmed.ncbi.nlm.nih.gov/26797640/
222.Popejoy, M.W., et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: A pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother, 2017. 72: 268.
https://pubmed.ncbi.nlm.nih.gov/27707990/
223.Sternbach, N., et al. Efficacy and safety of ceftazidime/avibactam: A systematic review and meta-analysis.
J Antimicrob Chemother, 2018. 73: 2021.
https://pubmed.ncbi.nlm.nih.gov/29659836/
224.van der Starre, W.E., et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother, 2011. 66: 650.
https://pubmed.ncbi.nlm.nih.gov/21123286/
225.Ren, H., et al. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial. Int Urol Nephrol, 2017. 49: 499.
https://pubmed.ncbi.nlm.nih.gov/28108978/
226.Wagenlehner, F.M., et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: A randomised, double-blind, phase 3 trial (ASPECT-cUTI). The Lancet, 2015. 385: 1949.
https://pubmed.ncbi.nlm.nih.gov/25931244/
227.Rudrabhatla, P., et al. Stopping the effective non-fluoroquinolone antibiotics at day 7 vs continuing until day 14 in adults with acute pyelonephritis requiring hospitalization: A randomized non-inferiority trial. PLoS ONE, 2018.
13: e0197302.
https://pubmed.ncbi.nlm.nih.gov/29768465/
228.Gould, C.V., et al. Guideline for prevention of catheter-associated urinary tract infections 2009. Infect Control Hosp Epidemiol, 2010. 31: 319.
https://pubmed.ncbi.nlm.nih.gov/20156062/
229.Magill, S.S., et al. Multistate point-prevalence survey of health care-associated infections. New Engl J Med, 2014. 370: 1198.
https://pubmed.ncbi.nlm.nih.gov/24670166/
230.Garibaldi, R.A., et al. Factors predisposing to bacteriuria during indwelling urethral catheterization. N Engl J Med, 1974. 291: 215.
https://pubmed.ncbi.nlm.nih.gov/4834750/
231.Kunin, C.M., et al. Prevention of catheter-induced urinary-tract infections by sterile closed drainage. N Engl
J Med, 1966. 274: 1155.
https://pubmed.ncbi.nlm.nih.gov/5934951/
232.Hartstein, A.I., et al. Nosocomial urinary tract infection: a prospective evaluation of 108 catheterized patients. Infect Control, 1981. 2: 380.
https://pubmed.ncbi.nlm.nih.gov/6795141/
233.Warren, J.W., et al. Fever, bacteremia, and death as complications of bacteriuria in women with long-term urethral catheters. J Infect Dis, 1987. 155: 1151.
https://pubmed.ncbi.nlm.nih.gov/3572035/
234.Classen, D.C., et al. Prevention of catheter-associated bacteriuria: clinical trial of methods to block three known pathways of infection. Am J Infect Control, 1991. 19: 136.
https://pubmed.ncbi.nlm.nih.gov/1863002/
235.Saint, S., et al. Preventing catheter-related bacteriuria: should we? Can we? How? Arch Intern Med, 1999. 159: 800.
https://pubmed.ncbi.nlm.nih.gov/10219925/
236.Maki, D.G., et al. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis, 2001. 7: 342.
https://pubmed.ncbi.nlm.nih.gov/11294737/
237.Li, F., et al. Risk factors for catheter-associated urinary tract infection among hospitalized patients: A systematic review and meta-analysis of observational studies. J Adv Nurs, 2019. 75: 517.
https://pubmed.ncbi.nlm.nih.gov/30259542/
238.Jacobsen, S.M., et al. Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev, 2008. 21: 26.
https://pubmed.ncbi.nlm.nih.gov/18202436/
239.Durant, D.J. Nurse-driven protocols and the prevention of catheter-associated urinary tract infections: A systematic review. Am J Infect Contr, 2017. 45: 1331.
https://pubmed.ncbi.nlm.nih.gov/28982611/
240.Mody, L., et al. A targeted infection prevention intervention in nursing home residents with indwelling devices a randomized clinical trial. JAMA Internal Med, 2015. 175: 714.
https://pubmed.ncbi.nlm.nih.gov/25775048/
241.Meddings, J., et al. Systematic review of interventions to reduce urinary tract infection in nursing home residents. J Hospital Med, 2017. 12: 356.
https://pubmed.ncbi.nlm.nih.gov/28459908/
242.Kachare, S.D., et al. Toward eliminating catheter-associated urinary tract infections in an academic health center. J Surg Res, 2014. 192: 280.
https://pubmed.ncbi.nlm.nih.gov/25150082/
243.Cao, Y., et al. Comparison of the preventive effect of urethral cleaning versus disinfection for catheter-associated urinary tract infections in adults: A network meta-analysis. Int J Infect Dis, 2018. 76: 102.
https://pubmed.ncbi.nlm.nih.gov/30243912/
244.Noto, M.J., et al. Chlorhexidine bathing and health care-associated infections: A randomized clinical trial. JAMA, 2015. 313: 369.
https://pubmed.ncbi.nlm.nih.gov/25602496/
245.Huang, H.P., et al. The efficacy of daily chlorhexidine bathing for preventing healthcare-associated infections in adult intensive care units. Korean J Int Med, 2016. 31: 1159.
https://pubmed.ncbi.nlm.nih.gov/27048258/
246.Li, M., et al. The effect of bladder catheterization on the incidence of urinary tract infection in laboring women with epidural analgesia: a meta-analysis of randomized controlled trials. Int Urogynecol J, 2019. 30: 1419.
https://pubmed.ncbi.nlm.nih.gov/30834958/
247.Gibson, K.E., et al. Indwelling urethral versus suprapubic catheters in nursing home residents: determining the safest option for long-term use. J Hospital Infect, 2019. 102: 219.
https://pubmed.ncbi.nlm.nih.gov/30056015/
248.Kidd, E.A., et al. Urethral (indwelling or intermittent) or suprapubic routes for short-term catheterisation in hospitalised adults. Cochrane Database Syst Rev, 2015. 2015: CD004203.
https://pubmed.ncbi.nlm.nih.gov/26661940/
249.Jamison, J., et al. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database Syst Rev, 2013. 18.
https://pubmed.ncbi.nlm.nih.gov/24249436
250.Kranz, J., et al. Catheter-Associated Urinary Tract Infections in Adult Patients. Dtsch Arztebl Int, 2020. 117: 83.
https://pubmed.ncbi.nlm.nih.gov/32102727/
251.Rognoni, C., et al. Intermittent catheterisation with hydrophilic and non-hydrophilic urinary catheters: systematic literature review and meta-analyses. BMC Urol, 2017. 17: 1.
https://pubmed.ncbi.nlm.nih.gov/28073354/
252.Tradewell, M., et al. Systematic review and practice policy statements on urinary tract infection prevention in adults with spina bifida. Transl Androl Urol, 2018. 7: S205.
https://pubmed.ncbi.nlm.nih.gov/29928619/
253.Akcam, F.Z., et al. An investigation of the effectiveness against bacteriuria of silver-coated catheters in short-term urinary catheter applications: A randomized controlled study. J Infect Chemother, 2019.
https://pubmed.ncbi.nlm.nih.gov/31030965/
254.Singh, R., et al. Randomized controlled trial of silver-alloy-impregnated suprapubic catheters versus standard suprapubic catheters in assessing urinary tract infection rates in urogynecology patients. Int Urogynecol J, 2019. 30: 779.
https://pubmed.ncbi.nlm.nih.gov/30145671/
255.Lam, T.B.L., et al. Types of indwelling urethral catheters for short-term catheterisation in hospitalised adults. Cochrane Database Syst Rev, 2014. 2014: CD004013.
https://pubmed.ncbi.nlm.nih.gov/25248140/
256.Menezes, F.G., et al. A randomized clinical trial comparing Nitrofurazone-coated and uncoated urinary catheters in kidney transplant recipients: Results from a pilot study. Transpl Infect Dis, 2019. 21: e13031.
https://pubmed.ncbi.nlm.nih.gov/30451342/
257.Bonfill, X., et al. Efficacy and safety of urinary catheters with silver alloy coating in patients with spinal cord injury: a multicentric pragmatic randomized controlled trial. The ESCALE trial. Spine J, 2017. 17: 1650.
https://pubmed.ncbi.nlm.nih.gov/28578163/
258.Lusardi, G., et al. Antibiotic prophylaxis for short-term catheter bladder drainage in adults. The Cochrane Database Syst Rev, 2013. 7: CD005428.
https://pubmed.ncbi.nlm.nih.gov/23824735/
259.Pickard, R., et al. Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT. Health Tech Assess, 2018. 22: 1.
https://pubmed.ncbi.nlm.nih.gov/29766842/
260.Cek, M., et al. Healthcare-associated urinary tract infections in hospitalized urological patients--a global perspective: results from the GPIU studies 2003-2010. World J Urol, 2014. 32: 1587.
https://pubmed.ncbi.nlm.nih.gov/24452449/
261.Darouiche, R.O., et al. Short versus long course of antibiotics for catheter-associated urinary tract infections in patients with spinal cord injury: a randomized controlled noninferiority trial. Arch Phys Med Rehabil, 2014. 95: 290.
https://pubmed.ncbi.nlm.nih.gov/24035770/
262.Saint, S., et al. Preventing Catheter-Associated Urinary Tract Infections. N Engl J Med, 2016. 375: 1298.
https://pubmed.ncbi.nlm.nih.gov/27682041/
263.Bone, R.C., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest, 1992. 101: 1644.
https://pubmed.ncbi.nlm.nih.gov/1303622/
264.Levy, M.M., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med, 2003. 31: 1250.
https://pubmed.ncbi.nlm.nih.gov/12682500/
265.Dellinger, R.P., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med, 2013. 39: 165.
https://pubmed.ncbi.nlm.nih.gov/23361625/
266.Martin, G.S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med, 2003. 348: 1546.
https://pubmed.ncbi.nlm.nih.gov/12700374/
267.Hotchkiss, R.S., et al. The pathophysiology and treatment of sepsis. N Engl J Med, 2003. 348: 138.
https://pubmed.ncbi.nlm.nih.gov/12519925/
268.Rosser, C.J., et al. Urinary tract infections in the critically ill patient with a urinary catheter. Am J Surg, 1999.
177: 287.
https://pubmed.ncbi.nlm.nih.gov/10326844/
269.Brun-Buisson, C., et al. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med, 2004. 30: 580.
https://pubmed.ncbi.nlm.nih.gov/14997295/
270.Tandogdu, Z., et al. Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013. World J Urol, 2016. 34: 1193.
https://pubmed.ncbi.nlm.nih.gov/26658886/
271.Wilson, M.L., et al. Principles and rocedures for blood cultures; Approved Guideline. Clin Lab Stand Inst, 2007.
https://clsi.org/media/1448/m47a_sample.pdf
272.Howell, M.D., et al. Management of Sepsis and Septic Shock. JAMA, 2017. 317: 847.
https://pubmed.ncbi.nlm.nih.gov/28114603/
273.Brunkhorst, F.M., et al. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med, 2000. 26 Suppl 2: S148.
https://pubmed.ncbi.nlm.nih.gov/18470710/
274.Angeletti, S., et al. Procalcitonin, MR-Proadrenomedullin, and Cytokines Measurement in Sepsis Diagnosis: Advantages from Test Combination. Dis Markers, 2015. 2015: 951532.
https://pubmed.ncbi.nlm.nih.gov/26635427/
275.Harbarth, S., et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med, 2001. 164: 396.
https://pubmed.ncbi.nlm.nih.gov/11500339/
276.Mikkelsen, M.E., et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med, 2009. 37: 1670.
https://pubmed.ncbi.nlm.nih.gov/19325467/
277.Carlet, J., et al. Guideliness for prevention of nosocomial infections in intensive care unit. Arnette Ed Paris
1994: 41. [No abstract available].
278.Riedl, C.R., et al. Bacterial colonization of ureteral stents. Eur Urol, 1999. 36: 53.
https://pubmed.ncbi.nlm.nih.gov/10364656/
279.DeGroot-Kosolcharoen, J., et al. Evaluation of a urinary catheter with a preconnected closed drainage bag. Infect Control Hosp Epidemiol, 1988. 9: 72.
https://pubmed.ncbi.nlm.nih.gov/3343502/
280.Rivers, E., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med, 2001. 345: 1368.
https://pubmed.ncbi.nlm.nih.gov/11794169/
281.Mouncey, P.R., et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med, 2015. 372: 1301.
https://pubmed.ncbi.nlm.nih.gov/25776532/
282.Investigators, A., et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med, 2014.
371: 1496.
https://pubmed.ncbi.nlm.nih.gov/25272316/
283.Pro, C.I., et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med, 2014. 370: 1683.
https://pubmed.ncbi.nlm.nih.gov/24635773/
284.Investigators, P., et al. Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis. N Engl
J Med, 2017. 376: 2223.
https://pubmed.ncbi.nlm.nih.gov/28320242/
285.Monnet, X., et al. Prediction of fluid responsiveness: an update. Ann Intensive Care, 2016. 6: 111.
https://pubmed.ncbi.nlm.nih.gov/27858374/
286.Dellinger, R.P., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med, 2004. 32: 858.
https://pubmed.ncbi.nlm.nih.gov/15090974/
287.Zhang, N., et al. Are Ureaplasma spp. a cause of nongonococcal urethritis? A systematic review and meta-analysis. PLoS ONE, 2014. 9: e113771.
https://pubmed.ncbi.nlm.nih.gov/25463970/
288.Horner, P.J., et al. 2016 European guideline on the management of non-gonococcal urethritis. Int J STD AIDS, 2016. 27: 928.
https://pubmed.ncbi.nlm.nih.gov/27147267/
289.Workowski, K.A., et al. Sexually Transmitted Diseases Treatment Guidelines, 2015. Centers for Disease Control and Prevention, 2015. 64: 1.
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm
290.Bartoletti, R., et al. Management of Urethritis: Is It Still the Time for Empirical Antibiotic Treatments? Eur Urol Focus, 2019. 5: 29.
https://pubmed.ncbi.nlm.nih.gov/30318465/
291.Jensen, J.S., et al. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol, 2016. 30: 1650.
https://pubmed.ncbi.nlm.nih.gov/27505296/
292.Miller, J.M., et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis, 2018. 67: e1.
https://pubmed.ncbi.nlm.nih.gov/29955859/
293.Wagenlehner, F.M.E., et al. The Presentation, Diagnosis, and Treatment of Sexually Transmitted Infections. Deutsches Arzteblatt Int, 2016. 113: 11.
https://pubmed.ncbi.nlm.nih.gov/26931526/
294.Sena, A.C., et al. Persistent and recurrent Trichomonas vaginalis infections: Epidemiology, treatment and management considerations. Exp Rev Anti-Infect Ther, 2014. 12: 673.
https://pubmed.ncbi.nlm.nih.gov/24555561/
295.Shigemura, K., et al. History and epidemiology of antibiotic susceptibilities of Neisseria gonorrhoeae. Current Drug Targets, 2015. 16: 272.
https://pubmed.ncbi.nlm.nih.gov/25410409/
296.Hathorn, E., et al. The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: A systematic review. Syst Rev, 2014. 3: 104.
https://pubmed.ncbi.nlm.nih.gov/25239090/
297.Lau, A., et al. The efficacy of azithromycin for the treatment of genital mycoplasma genitalium: A systematic review and meta-analysis. Clin Infect Dis, 2015. 61: 1389.
https://pubmed.ncbi.nlm.nih.gov/26240201/
298.Manhart, L.E., et al. Efficacy of Antimicrobial Therapy for Mycoplasma genitalium Infections. Clin Infect Dis, 2015. 61: S802.
https://pubmed.ncbi.nlm.nih.gov/26602619/
299.Paez-Canro, C., et al. Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. Cochrane Database Syst Rev, 2019. 2019: CD010871.
https://pubmed.ncbi.nlm.nih.gov/30682211/
300.Atkinson, L.M., et al. ‘The waiting game’: are current chlamydia and gonorrhoea near-patient/point-of-care tests acceptable to service users and will they impact on treatment? Int J STD AIDS, 2016. 27: 650.
https://pubmed.ncbi.nlm.nih.gov/26092579/
301.Harding-Esch, E.M., et al. Impact of deploying multiple point-of-care tests with a sample first’ approach on a sexual health clinical care pathway. A service evaluation. Sexually Transmitted Infections, 2017. 93: 424.
https://pubmed.ncbi.nlm.nih.gov/28159916/
302.Mensforth, S., et al. Auditing the use and assessing the clinical utility of microscopy as a point-of-care test for Neisseria gonorrhoeae in a Sexual Health clinic. Int J STD AIDS, 2018. 29: 157.
https://pubmed.ncbi.nlm.nih.gov/28705094/
303.Moi, H., et al. Microscopy of Stained Urethral Smear in Male Urethritis; Which Cutoff Should be Used? Sex Trans Dis, 2017. 44: 189.
https://pubmed.ncbi.nlm.nih.gov/28178118/
304.Sarier, M., et al. Microscopy of Gram-stained urethral smear in the diagnosis of urethritis: Which threshold value should be selected? Andrologia, 2018. 50: e13143.
https://pubmed.ncbi.nlm.nih.gov/30238498/
305.Falk, L., et al. Time to eradication of Mycoplasma genitalium after antibiotic treatment in men and women.
J Antimicrob Chemother, 2015. 70: 3134.
https://pubmed.ncbi.nlm.nih.gov/26283670/
306.Khosropour, C.M., et al. Efficacy of standard therapies against Ureaplasma species and persistence among men with nongonococcal urethritis enrolled in a randomised controlled trial. Sexually Transmitted Infections, 2015.
91: 308.
https://pubmed.ncbi.nlm.nih.gov/25616607/
307.Kirkcaldy, R.D., et al. Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance - The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014. Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002), 2016. 65: 1.
https://pubmed.ncbi.nlm.nih.gov/27414503/
308.Ong, J.J., et al. Should female partners of men with non-gonococcal urethritis, negative for Chlamydia trachomatis and Mycoplasma genitalium, be informed and treated? Clinical outcomes from a partner study of heterosexual men with NGU. Sex Trans Dis, 2017. 44: 126.
https://pubmed.ncbi.nlm.nih.gov/28079749/
309.Read, T.R.H., et al. Azithromycin 1.5g over 5 days compared to 1g single dose in urethral mycoplasma genitalium: Impact on treatment outcome and resistance. Clin Infect Dis, 2017. 64: 250.
https://pubmed.ncbi.nlm.nih.gov/28011607/
310.Read, T.R.H., et al. Use of pristinamycin for Macrolide-Resistant mycoplasma genitalium infection. Emerging Infect Dis, 2018. 24: 328.
https://pubmed.ncbi.nlm.nih.gov/29350154/
311.Salado-Rasmussen, K., et al. Mycoplasma genitalium testing pattern and macrolide resistance: A Danish nationwide retrospective survey. Clin Infect Dis, 2014. 59: 24.
https://pubmed.ncbi.nlm.nih.gov/24729494/
312.Soda, M., et al. Evaluation of the microbiological efficacy of a single 2-gram dose of extended-release azithromycin by population pharmacokinetics and simulation in Japanese patients with gonococcal urethritis. Antimicrobial Agents Chemother, 2018. 62: e01409.
https://pubmed.ncbi.nlm.nih.gov/29038284/
313.Takahashi, S., et al. Clinical efficacy of a single two Gram dose of azithromycin extended release for male patients with urethritis. Antibiotics, 2014. 3: 109.
https://pubmed.ncbi.nlm.nih.gov/27025738/
314.Unemo, M., et al. Five-day azithromycin treatment regimen for mycoplasma genitalium infection also effectively eradicates chlamydia trachomatis. Acta Dermato-Venereologica, 2015. 95: 730.
https://pubmed.ncbi.nlm.nih.gov/25823977/
315.Yasuda, M., et al. A single 2 g oral dose of extended-release azithromycin for treatment of gonococcal urethritis. J Antimicrob Chemother, 2014. 69: 3116.
https://pubmed.ncbi.nlm.nih.gov/24948703/
316.Yuan, Z., et al. Randomized controlled clinical trial on the efficacy of fosfomycin trometamol for uncomplicated gonococcal urethritis in men. Clin Microbiol Infect, 2016. 22: 507.
https://pubmed.ncbi.nlm.nih.gov/27064136/
317.Berntsson, M., et al. Viral and bacterial aetiologies of male urethritis: findings of a high prevalence of Epstein-Barr virus. Int J STD AIDS, 2010. 21: 191.
https://pubmed.ncbi.nlm.nih.gov/20215624/
318.Couldwell, D.L., et al. Ureaplasma urealyticum is significantly associated with non-gonococcal urethritis in heterosexual Sydney men. Int J STD AIDS, 2010. 21: 337.
https://pubmed.ncbi.nlm.nih.gov/20498103/
319.Rietmeijer, C.A., et al. Recalibrating the Gram stain diagnosis of male urethritis in the era of nucleic acid amplification testing. Sex Transm Dis, 2012. 39: 18.
https://pubmed.ncbi.nlm.nih.gov/22183839/
320.Centers for Disease Control, et al. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014. MMWR Recomm Rep, 2014. 63: 1.
https://pubmed.ncbi.nlm.nih.gov/24622331/
321.Bissessor, M., et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis, 2015. 60: 1228.
https://pubmed.ncbi.nlm.nih.gov/25537875/
322.Kirkcaldy, R.D., et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis, 2014. 59: 1083.
https://pubmed.ncbi.nlm.nih.gov/25031289/
323.Kojima, M., et al. Single-dose treatment of male patients with gonococcal urethritis using 2g spectinomycin: microbiological and clinical evaluations. Int J Antimicrob Agents, 2008. 32: 50.
https://pubmed.ncbi.nlm.nih.gov/18539003/
324.Lanjouw, E., et al. 2015 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS, 2016. 27: 333.
https://pubmed.ncbi.nlm.nih.gov/26608577/
325.Lau, C.Y., et al. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis, 2002. 29: 497.
https://pubmed.ncbi.nlm.nih.gov/12218839/
326.Moran, J.S., et al. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis, 1995. 20 Suppl 1: S47.
https://pubmed.ncbi.nlm.nih.gov/7795109/
327.Unemo, M., et al. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev, 2014. 27: 587.
https://pubmed.ncbi.nlm.nih.gov/24982323/
328.Muratani, T., et al. Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol, 2008. 15: 837.
https://pubmed.ncbi.nlm.nih.gov/18665871/
329.Alexander, R.B., et al. Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology, 1998. 52: 744.
https://pubmed.ncbi.nlm.nih.gov/9801092/
330.Alexander, R.B., et al. Chronic prostatitis: results of an Internet survey. Urology, 1996. 48: 568.
https://pubmed.ncbi.nlm.nih.gov/8886062/
331.Zermann, D.H., et al. Neurourological insights into the etiology of genitourinary pain in men. J Urol, 1999. 161: 903.
https://pubmed.ncbi.nlm.nih.gov/10022711/
332.Perletti, G., et al. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev, 2013: CD009071.
https://pubmed.ncbi.nlm.nih.gov/23934982/
333.Dadashpour. M, et al. Acute Prostatitis After Transrectal Ultrasound-guided Prostate Biopsy: Comparing Two Different Antibiotic Prophylaxis Regimen. Biomed Pharmacol J, 2016. 9: 593.
https://pubmed.ncbi.nlm.nih.gov//
334.Schaeffer, A.J., et al. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol, 2005. 174: 161.
https://pubmed.ncbi.nlm.nih.gov/15947609/
335.Skerk, V., et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents, 2003. 21: 457.
https://pubmed.ncbi.nlm.nih.gov/12727080/
336.Vickovic, N., et al. Metronidazole 1.5 gram dose for 7 or 14 days in the treatment of patients with chronic prostatitis caused by Trichomonas vaginalis: A randomized study. J Chemother, 2010. 22: 364.
https://pubmed.ncbi.nlm.nih.gov/21123162/
337.Cai, T., et al. Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. Int J Antimicrob Agents, 2009. 33: 549.
https://pubmed.ncbi.nlm.nih.gov/19181486/
338.Aliaev Iu, G., et al. [Wardenafil in combined treatment of patients with chronic bacterial prostatitis]. Urologiia, 2008: 52.
https://pubmed.ncbi.nlm.nih.gov/19256057/
339.Lipsky, B.A., et al. Treatment of bacterial prostatitis. Clin Infect Dis, 2010. 50: 1641.
https://pubmed.ncbi.nlm.nih.gov/20459324/
340.Wise, G.J., et al. Atypical infections of the prostate. Curr Prostate Rep, 2008. 6: 86.
https://link.springer.com/article/10.1007/s11918-008-0014-2
341.Turner, J.A., et al. Validity and responsiveness of the national institutes of health chronic prostatitis symptom index. J Urol, 2003. 169: 580.
https://pubmed.ncbi.nlm.nih.gov/12544311/
342.Zegarra Montes, L.Z., et al. Semen and urine culture in the diagnosis of chronic bacterial prostatitis. Int Braz
J Urol, 2008. 34: 30.
https://pubmed.ncbi.nlm.nih.gov/18341719/
343.Budia, A., et al. Value of semen culture in the diagnosis of chronic bacterial prostatitis: a simplified method. Scand J Urol Nephrol, 2006. 40: 326.
https://pubmed.ncbi.nlm.nih.gov/16916775/
344.Skerk, V., et al. The role of unusual pathogens in prostatitis syndrome. Int J Antimicrob Agents, 2004. 24 Suppl
1: S53.
https://pubmed.ncbi.nlm.nih.gov/15364308/
345.Schneider, H., et al. The 2001 Giessen Cohort Study on patients with prostatitis syndrome--an evaluation of inflammatory status and search for microorganisms 10 years after a first analysis. Andrologia, 2003. 35: 258.
https://pubmed.ncbi.nlm.nih.gov/14535851/
346.Naber, K.G., et al., Prostatitits, epididymitis and orchitis, In: Infectious diseases, D. Armstrong & J. Cohen, Editors. 1999, Mosby: London.
347.Badalyan, R.R., et al. Chlamydial and ureaplasmal infections in patients with nonbacterial chronic prostatitis. Andrologia, 2003. 35: 263.
https://pubmed.ncbi.nlm.nih.gov/14535852/
348.Berger, R.E., Epididymitis., In: Sex Trans Dis, K.K. Holmes, P.-A. Mardh, P.F. Sparling & P.J. Wiesner, Editors. 1984, McGraw-Hill: New York.
349.Robinson, A.J., et al. Acute epididymitis: why patient and consort must be investigated. Br J Urol, 1990. 66: 642.
https://pubmed.ncbi.nlm.nih.gov/2265337/
350.Schaeffer, A.J. Prostatitis: US perspective. Int J Antimicrob Agents, 1999. 11: 205.
https://pubmed.ncbi.nlm.nih.gov/10394972/
351.Krieger, J.N., et al. NIH consensus definition and classification of prostatitis. Jama, 1999. 282: 236.
https://pubmed.ncbi.nlm.nih.gov/10422990/
352.Workshop Committee of the national institute of diabetes and digestive and kidney diease (NIDDK), Chronic prostatitis workshop. 1995: Bethesda, Maryland.
353.Krieger, J.N., et al. Chronic pelvic pains represent the most prominent urogenital symptoms of “chronic prostatitis”. Urology, 1996. 48: 715.
https://pubmed.ncbi.nlm.nih.gov/8911515/
354.Nickel, J.C. Effective office management of chronic prostatitis. Urol Clin North Am, 1998. 25: 677.
https://pubmed.ncbi.nlm.nih.gov/10026774/
355.Etienne, M., et al. Performance of the urine leukocyte esterase and nitrite dipstick test for the diagnosis of acute prostatitis. Clin Infect Dis, 2008. 46: 951.
https://pubmed.ncbi.nlm.nih.gov/18288905/
356.Meares, E.M., et al. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol, 1968.
5: 492.
https://pubmed.ncbi.nlm.nih.gov/4870505/
357.Nickel, J.C., et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol, 2006. 176: 119.
https://pubmed.ncbi.nlm.nih.gov/16753385/
358.Doble, A., et al. Ultrasonographic findings in prostatitis. Urol Clin North Am, 1989. 16: 763.
https://pubmed.ncbi.nlm.nih.gov/2683305/
359.Papp, J.R., et al. Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae — 2014. MMWR Recomm Rep, 2014. 63: 1.
https://www.researchgate.net/publication/262047016
360.Polascik, T.J., et al. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol, 1999. 162: 293.
https://pubmed.ncbi.nlm.nih.gov/10411025/
361.Wagenlehner, F.M., et al. Bacterial prostatitis. World J Urol, 2013. 31: 711.
https://pubmed.ncbi.nlm.nih.gov/23519458/
362.Gill, B.C., et al. Bacterial prostatitis. Curr Opin Infect Dis, 2016. 29: 86.
https://pubmed.ncbi.nlm.nih.gov/26555038/
363.Wagenlehner, F.M., et al. Prostatitis: the role of antibiotic treatment. World J Urol, 2003. 21: 105.
https://pubmed.ncbi.nlm.nih.gov/12687400/
364.Krieger, J.N. Recurrent lower urinary tract infections in men. J New Rem Clin, 1998. 47: 4.
365.Litwin, M.S., et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol, 1999. 162: 369.
https://pubmed.ncbi.nlm.nih.gov/10411041/
366.Schaeffer, A.J., et al. Summary consensus statement: diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 2003. 43: 1.
https://pubmed.ncbi.nlm.nih.gov/12521576/
367.Bjerklund Johansen, T.E., et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol, 1998. 34: 457.
https://pubmed.ncbi.nlm.nih.gov/9831786/
368.Cai, T., et al. Clinical and microbiological efficacy of prulifloxacin for the treatment of chronic bacterial prostatitis due to Chlamydia trachomatis infection: results from a prospective, randomized and open-label study. Methods Find Exp Clin Pharmacol, 2010. 32: 39.
https://pubmed.ncbi.nlm.nih.gov/20383345/
369.Smelov, V., et al. Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome. Andrologia, 2005. 37: 61.
https://pubmed.ncbi.nlm.nih.gov/16026425/
370.Ohkawa, M., et al. Antimicrobial treatment for chronic prostatitis as a means of defining the role of Ureaplasma urealyticum. Urol Int, 1993. 51: 129.
https://pubmed.ncbi.nlm.nih.gov/8249222/
371.Jimenez-Cruz, J.F., et al. Treatment of chronic prostatitis: intraprostatic antibiotic injections under echography control. J Urol, 1988. 139: 967.
https://pubmed.ncbi.nlm.nih.gov/3283385/
372.Mayersak, J.S. Transrectal ultrasonography directed intraprostatic injection of gentamycin-xylocaine in the management of the benign painful prostate syndrome. A report of a 5 year clinical study of 75 patients. Int Surg, 1998. 83: 347.
https://pubmed.ncbi.nlm.nih.gov/10096759/
373.Hua, L.X., et al. [The diagnosis and treatment of acute prostatitis: report of 35 cases]. Zhonghua Nan Ke Xue, 2005. 11: 897.
https://pubmed.ncbi.nlm.nih.gov/16398358/
374.Yoon, B.I., et al. Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect Chemother, 2012. 18: 444.
https://pubmed.ncbi.nlm.nih.gov/22215226/
375.Ludwig, M., et al. Diagnosis and therapeutic management of 18 patients with prostatic abscess. Urology, 1999. 53: 340.
https://pubmed.ncbi.nlm.nih.gov/9933051/
376.Chou, Y.H., et al. Prostatic abscess: transrectal color Doppler ultrasonic diagnosis and minimally invasive therapeutic management. Ultrasound Med Biol, 2004. 30: 719.
https://pubmed.ncbi.nlm.nih.gov/15219951/
377.Çek, M., et al. Acute and Chronic Epididymitis in EAU-EBU Update Series. Eur Urol Suppl 2017. 16: 124.
https://www.sciencedirect.com/science/article/abs/pii/S1569905617300568
378.Pilatz, A., et al. Acute epididymitis revisited: impact of molecular diagnostics on etiology and contemporary guideline recommendations. Eur Urol, 2015. 68: 428.
https://pubmed.ncbi.nlm.nih.gov/25542628/
379.Harnisch, J.P., et al. Aetiology of acute epididymitis. Lancet, 1977. 1: 819.
https://pubmed.ncbi.nlm.nih.gov/67333/
380.Fujisawa, M., et al. Risk factors for febrile genito-urinary infection in the catheterized patients by with spinal cord injury-associated chronic neurogenic lower urinary tract dysfunction evaluated by urodynamic study and cystography: a retrospective study. World J Urol, 2020. 38: 733.
https://pubmed.ncbi.nlm.nih.gov/30949801/
381.Street, E., et al. The 2016 European guideline on the management of epididymo-orchitis. IUSTI, 2016.
https://pubmed.ncbi.nlm.nih.gov/28632112/
382.Chirwa, M., et al. United Kingdom British association for sexual health and HIV national guideline for the management of epididymo-orchitis, 2020. Int J STD AIDS, 2021.
https://pubmed.ncbi.nlm.nih.gov/34009058/
383.Abbara, A., et al. Etiology and management of genitourinary tuberculosis. Nat Rev Urol, 2011. 8: 678.
https://pubmed.ncbi.nlm.nih.gov/22157940/
384.Martin, K., et al. Assessing the utility of ultrasound and urinalysis for patients with possible epididymo-orchitis - a retrospective study. Open Access Emerg Med, 2020. 12: 47.
https://pubmed.ncbi.nlm.nih.gov/32214857/
385.Capet, J., et al. Is follow-up ultrasound necessary after acute epididymitis? A retrospective analysis from a large university hospital. Scan J Urol, 2018. 52: 445.
https://pubmed.ncbi.nlm.nih.gov/30600755/
386.Sadahira, T., et al. Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue. J Infect Chemother, 2017. 23: 214.
https://pubmed.ncbi.nlm.nih.gov/28089362/
387.Street, E., et al. BASHH 2010 United Kingdom national guideline for the management of epididymo-orchitis. 2010.
https://pubmed.ncbi.nlm.nih.gov/21729951/
388.Fifer, H., et al. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae. Int J STD AIDS, 2020. 31: 4.
https://pubmed.ncbi.nlm.nih.gov/31870237/
389.Eickhoff, J.H., et al. A double-blind, randomized, controlled multicentre study to compare the efficacy of ciprofloxacin with pivampicillin as oral therapy for epididymitis in men over 40 years of age. BJU Int, 1999. 84: 827.
https://pubmed.ncbi.nlm.nih.gov/10532980/
390.Banyra, O., et al. Acute epididymo-orchitis: Relevance of local classification and partner’s follow-up. Centr Eur
J Urol, 2019. 72: 324.
https://pubmed.ncbi.nlm.nih.gov/31720038/
391.Pilatz, A., et al. Impact of bacterial epididymitis on semen quality after antibiotic treatment. J Urol, 2012. 1): e443.
https://pubmed.ncbi.nlm.nih.gov/70720788/
392.Haddadeen, C., et al. Comparative regional audit of urology and genito-urinary departments in the management of acute epididymo-orchitis. HIV Medicine, 2010. 11: 45.
https://pubmed.ncbi.nlm.nih.gov/70186144/
393.Nicholson, A., et al. Management of epididymo-orchitis in primary care: Results from a large UK primary care database. Brit J Gen Pract, 2010. 60: e407.
https://pubmed.ncbi.nlm.nih.gov/20883615/
394.Andersen, B., et al. Impact of intensified testing for urogenital Chlamydia trachomatis infections: a randomised study with 9-year follow-up. Sex Transm Infect, 2011. 87: 156.
https://pubmed.ncbi.nlm.nih.gov/21097811/
395.Chennamsetty, A., et al. Contemporary diagnosis and management of Fournier’s gangrene. Ther Adv Urol, 2015. 7: 203.
https://pubmed.ncbi.nlm.nih.gov/26445600/
396.Eke, N. Fournier’s gangrene: a review of 1726 cases. Br J Surg, 2000. 87: 718.
https://pubmed.ncbi.nlm.nih.gov/10848848/
397.Subrahmanyam, U., et al. Honey dressing beneficial in treatment of fournier’s gangrene. Indian J Surg, 2004.
66: 75.
https://tspace.library.utoronto.ca/retrieve/4733/IndianJournalofSurgery_2004_66_2_75_12453.pdf
398.Jallali, N., et al. Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. Am J Surg, 2005. 189: 462.
https://pubmed.ncbi.nlm.nih.gov/15820462/
399.Karian, L.S., et al. Reconstruction of Defects After Fournier Gangrene: A Systematic Review. Eplasty, 2015. 15: e18.
https://pubmed.ncbi.nlm.nih.gov/26171090/
400.Furr, J., et al. Contemporary Trends in the Inpatient Management of Fournier’s Gangrene: Predictors of Length of Stay and Mortality Based on Population-based Sample. Urology, 2017. 102: 79.
https://pubmed.ncbi.nlm.nih.gov/27693572/
401.Kim, S.Y., et al. A Contemporary Analysis of Fournier Gangrene Using the National Surgical Quality Improvement Program. Urology, 2015.
https://pubmed.ncbi.nlm.nih.gov/25770725/
402.Sorensen, M.D., et al. Fournier’s Gangrene: Epidemiology and Outcomes in the General US Population. Urol Int, 2016. 97: 249.
https://pubmed.ncbi.nlm.nih.gov/27172977/
403.Roghmann, F., et al. Is there a need for the Fournier’s gangrene severity index? Comparison of scoring systems for outcome prediction in patients with Fournier’s gangrene. BJU Int, 2012. 110: 1359.
https://pubmed.ncbi.nlm.nih.gov/22494217/
404.Lauerman, M., et al. Less is More? Antibiotic duration and outcomes in fournier’s gangrene. J Trauma Acute Care Surg, 2017.
https://pubmed.ncbi.nlm.nih.gov/28538648/
405.Li, C., et al. Hyperbaric oxygen therapy as an adjuvant therapy for comprehensive treatment of Fournier’s gangrene. Urol Int, 2015. 94: 453.
https://pubmed.ncbi.nlm.nih.gov/25677386/
406.Stevens, D.L., et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis, 2014. 59: 147.
https://pubmed.ncbi.nlm.nih.gov/24947530/
407.Lyu, Z., et al. Human papillomavirus in semen and the risk for male infertility: A systematic review and meta-analysis. BMC Infect Dis, 2017. 17: 714.
https://pubmed.ncbi.nlm.nih.gov/29121862/
408.Rodriguez-alvarez, M.I., et al. Prevalence and risk factors of human papillomavirus in male patients: A systematic review and meta-analysis. Int J Environmental Res Public Health, 2018. 15: 2210.
https://pubmed.ncbi.nlm.nih.gov/30309014/
409.Vaccarella, S., et al. Clustering of human papillomavirus (HPV) types in the male genital tract: The HPV in men (HIM) study. J Infect Dis, 2011. 204: 1500.
https://pubmed.ncbi.nlm.nih.gov/21908729/
410.Nakashima, K., et al. Risk factors for human papillomavirus detection in urine samples of heterosexual men visiting urological clinics in Japan. J Infect Chemother, 2018. 24: 713.
https://pubmed.ncbi.nlm.nih.gov/29759898/
411.Luttmer, R., et al. Presence of human papillomavirus in semen in relation to semen quality. Human Reprod, 2016. 31: 280.
https://pubmed.ncbi.nlm.nih.gov/26724799/
412.Souho, T., et al. Human papillomavirus infection and fertility alteration: A systematic review. PLoS ONE, 2015.
10: e0126936.
https://pubmed.ncbi.nlm.nih.gov/25992782/
413.Azevedo J, et al. Epidemiology of human papillomavirus on anogenital warts in Portugal - The HERCOLES study. J Eur Acad Dermatol Venereol, 2017. 31: 1342.
https://pubmed.ncbi.nlm.nih.gov/28485812/
414.Wei, F., et al. Sex Differences in the Incidence and Clearance of Anogenital Human Papillomavirus Infection in Liuzhou, China: An Observational Cohort Study. Clin Infect Dis, 2020. 70: 82.
https://pubmed.ncbi.nlm.nih.gov/30852604/
415.Harder, T., et al. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: A systematic review. BMC Med, 2018. 16: 110.
https://pubmed.ncbi.nlm.nih.gov/30016957/
416.Shigeishi, H., et al. Risk Factors for Oral Human Papillomavirus Infection in Healthy Individuals: A Systematic Review and Meta-Analysis. J Clin Med Res, 2016. 8: 721.
https://pubmed.ncbi.nlm.nih.gov/27635177/
417.Tam, S., et al. The epidemiology of oral human papillomavirus infection in healthy populations: A systematic review and meta-analysis. Oral Oncol, 2018. 82: 91.
https://pubmed.ncbi.nlm.nih.gov/29909908/
418.Dalla Torre D, et al. The impact of sexual behavior on oral HPV infections in young unvaccinated adults. Clin Oral Invest, 2016. 20: 1551.
https://pubmed.ncbi.nlm.nih.gov/26526324/
419.Geskus Rb, et al. Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men: estimates and risk factors. AIDS (London, England), 2016. 30: 37.
https://pubmed.ncbi.nlm.nih.gov/26355673/
420.Hebnes, J.B., et al. Prevalence of genital human papillomavirus among men in Europe: Systematic review and meta-analysis. J Sex Med, 2014. 11: 2630.
https://pubmed.ncbi.nlm.nih.gov/25088239/
421.Kaderli, R., et al. The impact of smoking on HPV infection and the development of anogenital warts. Int
J Colorectal Dis, 2014. 29: 899.
https://pubmed.ncbi.nlm.nih.gov/24935346/
422.Liu, M., et al. Transmission of genital human papillomavirus infection in couples: a population-based cohort study in rural China. Sci Rep, 2015. 5: 10986.
https://pubmed.ncbi.nlm.nih.gov/26204471/
423.Taylor, S., et al. The incidence, clearance and persistence of non-cervical human papillomavirus infections:
A systematic review of the literature. BMC Infect Dis, 2016. 16: 293.
https://pubmed.ncbi.nlm.nih.gov/27301867/
424.Albero, G., et al. Male circumcision and prevalence of genital human papillomavirus infection in men: A multinational study. BMC Infect Dis, 2013. 13: 18.
https://pubmed.ncbi.nlm.nih.gov/23327450/
425.Lam, J.U., et al. Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. J Med screening, 2014. 21: 38.
https://pubmed.ncbi.nlm.nih.gov/24488594/
426.Larke, N., et al. Male circumcision and human papillomavirus infection in men: A systematic review and meta-analysis. J Infect Dis, 2011. 204: 1375.
https://pubmed.ncbi.nlm.nih.gov/21965090/
427.Liu, Z., et al. Penises not required: a systematic review of the potential for human papillomavirus horizontal transmission that is non-sexual or does not include penile penetration. Sex Health, 2016. 13: 10.
https://pubmed.ncbi.nlm.nih.gov/26433493/
428.Albero, G., et al. Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Trans Dis, 2012. 39: 104.
https://pubmed.ncbi.nlm.nih.gov/22249298/
429.Zaak, D., et al. Recurrence of condylomata acuminata of the urethra after conventional and fluorescence-controlled Nd:YAG laser treatment. Urology, 2003. 61: 1011.
https://pubmed.ncbi.nlm.nih.gov/12736026/
430.Vives, A., et al. Urethral condylomas in men: experience in 123 patients without previous treatment. Int J STD AIDS, 2016. 27: 39.
https://pubmed.ncbi.nlm.nih.gov/25712107/
431.Gilson, R., et al. 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol, 2020. 34: 1644.
https://pubmed.ncbi.nlm.nih.gov/32735077/
432.Edwards, L., et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol, 1998. 134: 25.
https://pubmed.ncbi.nlm.nih.gov/9449906/
433.Saiag, P., et al. Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. Br
J Dermatol, 2009. 161: 904.
https://pubmed.ncbi.nlm.nih.gov/19466962/
434.Grillo-Ardila, C.F., et al. Imiquimod for anogenital warts in non-immunocompromised adults. Cochrane Database Syst Rev, 2014: CD010389.
https://pubmed.ncbi.nlm.nih.gov/25362229/
435.Tatti, S., et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol, 2008. 111: 1371.
https://pubmed.ncbi.nlm.nih.gov/18515521/
436.Puviani, M., et al. Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial. Int J STD AIDS, 2019. 30: 131.
https://pubmed.ncbi.nlm.nih.gov/30236042/
437.Werner, R.N., et al. Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis. Sex Transm Infect, 2017. 93: 155.
https://pubmed.ncbi.nlm.nih.gov/27803240/
438.Camargo, C.L., et al. A prospective, open, comparative study of 5% potassium hydroxide solution versus cryotherapy in the treatment of genital warts in men. An Bras Dermatol, 2014. 89: 236.
https://pubmed.ncbi.nlm.nih.gov/24770498/
439.Kodner, C.M., et al. Management of genital warts. Am Fam Physician, 2004. 70: 2335.
https://pubmed.ncbi.nlm.nih.gov/15617297/
440.Scheinfeld, N., et al. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J, 2006. 12: 5.
https://pubmed.ncbi.nlm.nih.gov/16638419/
441.Barton, S., et al. Effectiveness of topical and ablative therapies in treatment of anogenital warts: a systematic review and network meta-analysis. BMJ Open, 2019. 9: e027765.
https://pubmed.ncbi.nlm.nih.gov/31676644/
442.Tobian, A.A., et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med, 2009. 360: 1298.
https://pubmed.ncbi.nlm.nih.gov/19321868/
443.Schmeler, K.M., et al. Expanding the benefits of HPV vaccination to boys and men. Lancet, 2016. 387: 1798.
https://pubmed.ncbi.nlm.nih.gov/27203488/
444.Rosales, R., et al. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Human Gene Therapy, 2014. 25: 1035.
https://pubmed.ncbi.nlm.nih.gov/25275724/
445.Mikamo, H., et al. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study. Vaccine, 2019. 37: 1651.
https://pubmed.ncbi.nlm.nih.gov/30797638/
446.Bergman, H., et al. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev, 2019. 2019: CD013479.
https://pubmed.ncbi.nlm.nih.gov/31755549/
447.Dibble, K.E., et al. A systematic literature review of HPV vaccination barriers among adolescent and young adult males. J Adolescent Young Adult Oncol, 2019. 8: 495.
https://pubmed.ncbi.nlm.nih.gov/31090474/
448.Richman A.R., et al. A randomized intervention study to evaluate whether electronic messaging can increase HPV vaccine uptake and knowledge. J Lower Genital tract Dis, 2016. 20: S28.
https://journals.lww.com/jlgtd/Fulltext/2016/04001/2016_ASCCP_Poster_Presentation_Abstracts.2.aspx
449.European Center for Disease Pervention and Control/World Health Organisation. Tuberculosis surveillance and monitoring in Europe 2021 (2019 data). ECDC/WHO. ISBN 978-92-9498-534-7.
450.Hayward, S.E., et al. Extrapulmonary tuberculosis among migrants in Europe, 1995 to 2017. Clinical Microbiol Infect, 2021. 27: 1347.
https://pubmed.ncbi.nlm.nih.gov/33352301/
451.Lawn, S.D., et al. Tuberculosis. Lancet, 2011. 378: 57.
https://pubmed.ncbi.nlm.nih.gov/21420161/
452.Kang, W., et al. Epidemiology of concurrent extrapulmonary tuberculosis in inpatients with extrapulmonary tuberculosis lesions in China: a large-scale observational multi-centre investigation. Int J Infect Dis, 2022. 115: 79.
https://pubmed.ncbi.nlm.nih.gov/34781005/
453.Vynnycky, E., et al. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect, 1997. 119: 183.
https://pubmed.ncbi.nlm.nih.gov/9363017/
454.World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. ISBN 978-92-4-000150-3, 2020.
https://www.who.int/publications/i/item/9789240001503
455.Lewinsohn, D.M., et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis, 2017. 64: 111.
https://pubmed.ncbi.nlm.nih.gov/28052967/
456.European Centre for Disease Prevention and Control. Mastering the basics of TB control: Development of a handbook on TB diagnostic methods. Stockholm, ECDC, 2011. ISBN 978-92-9193-242-9.
457.Ye, Y., et al. Clinical Features and Drug-Resistance Profile of Urinary Tuberculosis in South-Western China: A Cross-sectional Study. Medicine (Baltimore), 2016. 95: e3537.
https://pubmed.ncbi.nlm.nih.gov/27175652/
458.Pingle, P., et al. Evaluation of Microscopy, Culture and PCR Methods in the Laboratory Diagnosis of Genito-urinary Tuberculosis. American Journal of Infectious Diseases and Microbiology, 2014. 2: 17.
http://pubs.sciepub.com/ajidm/2/1/4/index.html
459.Sun, L., et al. Rapid diagnosis in early stage renal tuberculosis by real-time polymerase chain reaction on renal biopsy specimens. Int J Tuberc Lung Dis, 2010. 14: 341.
https://pubmed.ncbi.nlm.nih.gov/20132626/
460.Kumar, P., et al. Diagnosis of renal tuberculosis by real-time polymerase chain reaction in renal biopsy sample. World Journal of Pharmaceutical and Medical Research, 2017. 3: 285.
https://www.wjpmr.com/home/article_abstract/709
461.World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection 2021 update. ISBN 978-92-4-002941-5
https://www.who.int/publications/i/item/9789240029415
462.World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection. Web Annex 4. Evidence synthesis and analysis. ISBN 978-92-4-001026-0.
https://apps.who.int/iris/handle/10665/334150
463.Hemal, A.K., et al. Polymerase chain reaction in clinically suspected genitourinary tuberculosis: comparison with intravenous urography, bladder biopsy, and urine acid fast bacilli culture. Urology, 2000. 56: 570.
https://pubmed.ncbi.nlm.nih.gov/11018606/
464.Muttarak, M., et al. Tuberculous epididymitis and epididymo-orchitis: sonographic appearances. AJR Am
J Roentgenol, 2001. 176: 1459.
https://pubmed.ncbi.nlm.nih.gov/11373214/
465.Yang, D.M., et al. Differential diagnosis of focal epididymal lesions with gray scale sonographic, color Doppler sonographic, and clinical features. J Ultrasound Med, 2003. 22: 135.
https://pubmed.ncbi.nlm.nih.gov/12562118/
466.Li, S., et al. A better understanding of testicular and/or epididymal tuberculosis based on clinical, ultrasonic, computed tomography, and magnetic resonance imaging features at a high-volume institute in the modern era. Quant Imaging Med Surgery, 2021. 11: 2465.
https://pubmed.ncbi.nlm.nih.gov/34079716/
467.Jing, J., et al. Vas deferens sonographic appearances of tuberculosis lesions of 19 cases of male genital systemic tuberculosis. Medicine (Baltimore), 2019. 98: e14843.
https://pubmed.ncbi.nlm.nih.gov/30882677/
468.Yang, D.M., et al. Chronic tuberculous epididymitis: color Doppler US findings with histopathologic correlation. Abdom Imaging, 2000. 25: 559.
https://pubmed.ncbi.nlm.nih.gov/10931999/
469.Rui, X., et al. Ultrasonographic diagnosis and typing of renal tuberculosis. Int J Urol, 2008. 15: 135.
https://pubmed.ncbi.nlm.nih.gov/18269447/
470.Radwan, A., et al. Multimodality Imaging of Genitourinary Tuberculosis. Curr Probl Diagn Radiol, 2021. 50: 867.
https://pubmed.ncbi.nlm.nih.gov/33272721/
471.Baumgarten, D.A., et al. Imaging and radiologic management of upper urinary tract infections. Urol Clin North Am, 1997. 24: 545.
https://pubmed.ncbi.nlm.nih.gov/9275978/
472.Muttarak, M., et al. Tuberculosis of the genitourinary tract: imaging features with pathological correlation. Singapore Med J, 2005. 46: 568.
https://pubmed.ncbi.nlm.nih.gov/16172781/
473.Wang, Y., et al. Computerised tomography and intravenous pyelography in urinary tuberculosis: A retrospective descriptive study. Int J Tubercu Lung Dis, 2015. 19: 1441.
https://pubmed.ncbi.nlm.nih.gov/26614184/
474.Sataa, S., et al. Imaging findings of urinary tuberculosis on computerized tomography versus excretory urography: Through 46 confirmed cases. Tunis Med, 2014. 92: 743.
https://pubmed.ncbi.nlm.nih.gov/25879600/
475.Wang, L.J., et al. Imaging findings of urinary tuberculosis on excretory urography and computerized tomography. J Urol, 2003. 169: 524.
https://pubmed.ncbi.nlm.nih.gov/12544301/
476.Birnbaum, B.A., et al. Extrarenal genitourinary tuberculosis: CT appearance of calcified pipe-stem ureter and seminal vesicle abscess. J Comput Assist Tomogr, 1990. 14: 653.
https://pubmed.ncbi.nlm.nih.gov/2370364/
477.Jung, Y.Y., et al. Genitourinary tuberculosis: comprehensive cross-sectional imaging. AJR Am J Roentgenol, 2005. 184: 143.
https://pubmed.ncbi.nlm.nih.gov/15615965/
478.Wang, L.J., et al. CT features of genitourinary tuberculosis. J Comput Assist Tomogr, 1997. 21: 254.
https://pubmed.ncbi.nlm.nih.gov/9071295/
479.Sharma, J.B., et al. Female genital tuberculosis: Revisited. Indian J Med Res, 2018. 148: S71.
https://pubmed.ncbi.nlm.nih.gov/30964083/
480.Mantica, G., et al. Genitourinary Tuberculosis: A Comprehensive Review of a Neglected Manifestation in Low-Endemic Countries. Antibiotics (Basel), 2021. 10.
https://pubmed.ncbi.nlm.nih.gov/26185345/
481.da Rocha, E.L., et al. Abdominal tuberculosis: a radiological review with emphasis on computed tomography and magnetic resonance imaging findings. Radiol Bras, 2015. 48: 181.
https://pubmed.ncbi.nlm.nih.gov/26185345/
482.Cheng, Y., et al. Multiparametric magnetic resonance imaging characteristics of prostate tuberculosis. Korean
J Radiol, 2015. 16: 846.
https://pubmed.ncbi.nlm.nih.gov/26175584/
483.Ahmadi, F., et al. Hysterosalpingographic Appearances of Female Genital Tract Tuberculosis: Part II: Uterus. Int
J Fertil Steril, 2014. 8: 13.
https://pubmed.ncbi.nlm.nih.gov/24696765/
484.Ahmadi, F., et al. Hysterosalpingographic appearances of female genital tract tuberculosis: part I. Fallopian tube. Int J Fertil Steril, 2014. 7: 245.
https://pubmed.ncbi.nlm.nih.gov/24520493/
485.Netter, A., et al. [Tuberculous endo-uterine symphysis; an anatomo-clinical and radiologically characteristic syndrome]. Gynecol Obstet (Paris), 1955. 54: 19.
https://pubmed.ncbi.nlm.nih.gov/14391756/
486.World Health Organization. WHO consolidated guidelines on tuberculosis Module 4: Treatment: Drug-susceptible tuberculosis treatment 2022. ISBN 978-92-4-004812-6.
https://www.who.int/publications/i/item/9789240048126
487.European Centre for Disease Pervention and Control. European Union Standards for Tuberculosis Care 2017 update. ISBN 978-92-9498-247-6.
488.Huang, Y., et al. Surgical management of tuberculous epididymo-orchitis: a retrospective study of 81 cases with long-term follow-up. BMC infect Dis, 2021. 21: 1068.
https://pubmed.ncbi.nlm.nih.gov/34654377/
489.Mittal, A., et al. Surgical Management of Genitourinary Tuberculosis: our Experience and review of literature. Pol Przegl Chir, 2020. 92: 1.
https://pubmed.ncbi.nlm.nih.gov/33408264/
490.Figueiredo, A.A., et al. Epidemiology of urogenital tuberculosis worldwide. Int J Urol, 2008. 15: 827.
https://pubmed.ncbi.nlm.nih.gov/18637157/
491.Mochalova, T.P., et al. Reconstructive surgery for treatment of urogenital tuberculosis: 30 years of observation. World J Surg, 1997. 21: 511.
https://pubmed.ncbi.nlm.nih.gov/9204739/
492.Gupta, N.P., et al. Reconstructive surgery for the management of genitourinary tuberculosis: a single center experience. J Urol, 2006. 175: 2150
https://pubmed.ncbi.nlm.nih.gov/16697825/
493.Kumar, A., et al. Can kidneys be saved in patients with urinary tuberculosis? A study in the era of modern chemotherapy and surgical armamentarium. Int J Urol, 2019. 26: 551.
https://pubmed.ncbi.nlm.nih.gov/30803052/
494.Pal, D.K., et al. Role of surgical intervention in genitourinary tuberculosis in the era of modern anti-tubercular chemotherapy. Sch. J. App. Med. Sci, 2015. 3: 1608.
https://journals.indexcopernicus.com/api/file/viewByFileId/362945.pdf
495.Li, X., et al. A Clinical Comparative Analysis of Retroperitoneal Laparoscopic Tuberculous Nephrectomy and Open Tuberculous Nephrectomy. J Laparoendosc Adv Surg Tech A, 2019. 29: 909.
https://pubmed.ncbi.nlm.nih.gov/30932738/
496.Zhang, S., et al. Open surgery versus retroperitoneal laparoscopic nephrectomy for renal tuberculosis: A retrospective study of 120 patients. PeerJ, 2016. 2016: e2708.
https://pubmed.ncbi.nlm.nih.gov/27917313/
497.Kim, H.H., et al. Laparoscopic nephrectomy for nonfunctioning tuberculous kidney. J Endourol, 2000. 14: 433.
https://pubmed.ncbi.nlm.nih.gov/10958566/
498.Han, W.K., et al. The feasibility of laparoendoscopic single-site nephrectomy: initial experience using home-made single-port device. Urology, 2010. 76: 862.
https://pubmed.ncbi.nlm.nih.gov/20110116/
499.Hemal, A.K., et al. Comparison of retroperitoneoscopic nephrectomy with open surgery for tuberculous nonfunctioning kidneys. J Urol, 2000. 164: 32.
https://pubmed.ncbi.nlm.nih.gov/10840418/
500.European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 – Healthcare-associated infections acquired in intensive care units. 2016.
501.CDC. Procedure-associated Module 9: Surgical Site Infection (SSI) Event. 2017.
https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf
502.Tanner, J., et al. Surgical hand antisepsis to reduce surgical site infection. Cochrane Database Syst Rev, 2016: CD004288.
https://pubmed.ncbi.nlm.nih.gov/26799160/
503.Webster, J., et al. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. Cochrane Database Syst Rev, 2015: CD004985.
https://pubmed.ncbi.nlm.nih.gov/25927093/
504.Tanner, J., et al. Preoperative hair removal to reduce surgical site infection. Cochrane Database Syst Rev, 2011: CD004122.
https://pubmed.ncbi.nlm.nih.gov/22071812/
505.Arnold, A., et al. Preoperative Mechanical Bowel Preparation for Abdominal, Laparoscopic, and Vaginal Surgery: A Systematic Review. J Minim Invasive Gynecol, 2015. 22: 737.
https://pubmed.ncbi.nlm.nih.gov/25881881/
506.Guenaga, K.F., et al. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database Syst Rev, 2011: CD001544.
https://pubmed.ncbi.nlm.nih.gov/21901677/
507.Dumville, J.C., et al. Preoperative skin antiseptics for preventing surgical wound infections after clean surgery. Cochrane Database Syst Rev, 2015: CD003949.
https://pubmed.ncbi.nlm.nih.gov/25897764/
508.Webster, J., et al. Use of plastic adhesive drapes during surgery for preventing surgical site infection. Cochrane Database Syst Rev, 2015: CD006353.
https://pubmed.ncbi.nlm.nih.gov/25901509/
509.Bonkat, G., et al. Non-molecular Methods to Detect Bacteriuria Prior to Urological Interventions: A Diagnostic Accuracy Systematic Review. Eur Urol Focus, 2017. 3: 535.
https://pubmed.ncbi.nlm.nih.gov/29627196/
510.European Center for Disease Control. Systematic review and evidence-based guidance on perioperative antibiotic prophylaxis. 2013.
511.Antibacterial prophylaxis in surgery: 2 - Urogenital, obstetric and gynaecological surgery. Drug Ther Bull, 2004. 42: 9.
https://pubmed.ncbi.nlm.nih.gov/38220205/
512.Benseler, A., et al. Antibiotic prophylaxis for urodynamic testing in women: a systematic review. Int Urogynecol J, 2021. 32: 27.
https://pubmed.ncbi.nlm.nih.gov/32845398/
513.Foon, R., et al. Prophylactic antibiotics to reduce the risk of urinary tract infections after urodynamic studies [Systematic Review]. Cochrane Database Syst Rev, 2012. 10: 10.
https://pubmed.ncbi.nlm.nih.gov/23076941/
514.Carey, M.M., et al. Should We Use Antibiotic Prophylaxis for Flexible Cystoscopy? A Systematic Review and Meta-Analysis. Urol Int, 2015. 95: 249.
https://pubmed.ncbi.nlm.nih.gov/26138144/
515.Garcia-Perdomo, H.A., et al. Efficacy of antibiotic prophylaxis in cystoscopy to prevent urinary tract infection: a systematic review and meta-analysis. Int Braz J Urol, 2015. 41: 412.
https://pubmed.ncbi.nlm.nih.gov/26200530/
516.Zeng, S., et al. Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy. Cochrane Database Syst Rev, 2019. 2: CD012305.
https://pubmed.ncbi.nlm.nih.gov/30789676/
517.Bradshaw, A.W., et al. Antibiotics are not necessary during routine cystoscopic stent removal: A randomized controlled trial at UC San Diego. Urol Ann, 2020. 12: 373.
https://pubmed.ncbi.nlm.nih.gov/33776335/
518.Lu, Y., et al. Antibiotic prophylaxis for shock wave lithotripsy in patients with sterile urine before treatment may be unnecessary: A systematic review and meta-analysis. J Urol, 2012. 188: 441.
https://pubmed.ncbi.nlm.nih.gov/52059642/
519.Mrkobrada, M., et al. CUA Guidelines on antibiotic prophylaxis for urologic procedures. Can Urol Assoc J, 2015. 9: 13.
https://pubmed.ncbi.nlm.nih.gov/25737749/
520.Hsieh, C.H., et al. The Effectiveness of Prophylactic Antibiotics with Oral Levofloxacin against Post-Shock Wave Lithotripsy Infectious Complications: A Randomized Controlled Trial. Surg Infect, 2016. 17: 346.
https://pubmed.ncbi.nlm.nih.gov/26910613/
521.Shafi, H., et al. Antibiotic prophylaxis in the prevention of urinary tract infection in patients with sterile urine before extracorporeal shock wave lithotripsy. Caspian J Intern Med, 2018. 9: 296.
https://pubmed.ncbi.nlm.nih.gov/30197776/
522.Liker, Y., et al. The role of antibiotics in patients with increased risk of infection during extracorporeal shock wave lithotripsy (ESWL) treatment. Marmara Med J, 1996. 9: 174.
https://pubmed.ncbi.nlm.nih.gov/26377368/
523.Deng, T., et al. Antibiotic prophylaxis in ureteroscopic lithotripsy: a systematic review and meta-analysis of comparative studies. BJU Int, 2018. 122: 29.
https://pubmed.ncbi.nlm.nih.gov/29232047/
524.Zhao, Z., et al. Recommended antibiotic prophylaxis regimen in retrograde intrarenal surgery: evidence from a randomised controlled trial. BJU Int, 2019. 124: 496.
https://pubmed.ncbi.nlm.nih.gov/31136070/
525.Qiao, L.D., et al. Evaluation of perioperative prophylaxis with fosfomycin tromethamine in ureteroscopic stone removal: an investigator-driven prospective, multicenter, randomized, controlled study. Int Urol Nephrol, 2018. 50: 427.
https://pubmed.ncbi.nlm.nih.gov/29290000/
526.Yu, J., et al. Antibiotic prophylaxis in perioperative period of percutaneous nephrolithotomy: a systematic review and meta-analysis of comparative studies. World J Urol, 2020. 38: 1685.
https://pubmed.ncbi.nlm.nih.gov/31562533/
527.Seyrek, M., et al. Perioperative prophylaxis for percutaneous nephrolithotomy: Randomized study concerning the drug and dosage. J Endourol, 2012. 26: 1431.
https://pubmed.ncbi.nlm.nih.gov/22612061/
528.Tuzel, E., et al. Prospective comparative study of two protocols of antibiotic prophylaxis in percutaneous nephrolithotomy. J Endourol, 2013. 27: 172.
https://pubmed.ncbi.nlm.nih.gov/22908891/
529.Omar, M., et al. Ciprofloxacin infusion versus third generation cephalosporin as a surgical prophylaxis for percutaneous nephrolithotomy: a randomized study. Centr Eur J Urol, 2019. 72: 57.
https://pubmed.ncbi.nlm.nih.gov/31011442/
530.Taken, K., et al. Comparison of Ceftriaxone and Cefazolin Sodium Antibiotic Prophylaxis in Terms of SIRS/Urosepsis Rates in Patients Undergoing Percutaneous Nephrolithotomy. J Urol Surg, 2019. 6: 111.
https://www.researchgate.net/publication/333236810
531.Dahm, P., et al. Evidence-based Urology. BMJ Books London, 2010: 50.
532.Bausch, K., et al. Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-Analysis. J Urol, 2021. 205: 987.
https://pubmed.ncbi.nlm.nih.gov/33284673/
533.Yang, J., et al. Prospective, randomized controlled study of the preventive effect of fosfomycin tromethamine on post-transurethral resection of bladder tumor urinary tract infection. Int J Urol, 2018. 25: 894.
https://pubmed.ncbi.nlm.nih.gov/29999216/
534.Sanaee, M.S., et al. Urinary tract infection prevention after midurethral slings in pelvic floor reconstructive surgery: A systematic review and meta-analysis. Acta Obstet Gynecol Scand, 2019. 98: 1514.
https://pubmed.ncbi.nlm.nih.gov/31112286/
535.Crawford, D., et al. Infectious Outcomes from Renal Tumor Ablation: Prophylactic Antibiotics or Not? Cardiovasc Intervent Radiol, 2018. 41: 1573.
https://pubmed.ncbi.nlm.nih.gov/30062444/
536.Pradere, B., et al. Non-antibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. J Urol, 2021. 205: 653.
https://pubmed.ncbi.nlm.nih.gov/33026903/
537.Lam, W., et al. Prostate cancer detection, tolerability and safety of transperineal prostate biopsy under local-anaesthesia vs standard transrectal biopsy in biopsy-naive men: a pragmatic, parallel group, randomized controlled study. BJU International, 2022. 129: 9.
https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.15675
538.Bennett, H.Y., et al. The global burden of major infectious complications following prostate biopsy. Epidemiol Infect, 2016. 144: 1784.
https://pubmed.ncbi.nlm.nih.gov/26645476/
539.Berry, B., et al. Comparison of complications after transrectal and transperineal prostate biopsy: a national population-based study. BJU Int, 2020. 126: 97.
https://pubmed.ncbi.nlm.nih.gov/32124525/
540.Castellani, D., et al. Infection Rate after Transperineal Prostate Biopsy with and without Prophylactic Antibiotics: Results from a Systematic Review and Meta-Analysis of Comparative Studies. J Urol, 2022. 207: 25.
https://pubmed.ncbi.nlm.nih.gov/34555932/
541.Basourakos, S.P., et al. Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis. Eur Urol Open Sci, 2022. 37: 53.
https://pubmed.ncbi.nlm.nih.gov/35243391/
542.Chernysheva, D.Y., et al. The first experience of transperineal prostate biopsy without antibiotic prophylaxis. Onkourologiya, 2021. 17: 46.
https://oncourology.abvpress.ru/oncur/article/view/1392?locale=en_US
543.Jacewicz, M., et al. Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial. Lancet Infect Dis, 2022.
https://pubmed.ncbi.nlm.nih.gov/35839791/
544.Abdulbaki, M.S., et al. Does the use of povidone iodine suppository decrease the infective complications of TRUS guided prostate biopsies? A randomized prospective study. QJM, 2020. 113.
https://academic.oup.com/qjmed/article/113/Supplement_1/hcaa070.024/5829649?login=false
545.Ergani, B., et al. Effect of rectal mucosa cleansing on acute prostatitis during prostate biopsy: A randomized prospective study. Turk J Urol, 2020. 46: 159.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053991/
546.Farooq, K., et al. Role of povidone-iodine-soaked gauze in preventing infectious complications followinf transrectal digital guided prostate biopsy. Journal of Postgraduate Medical Institute, 2021. 35: 225.
https://jpmi.org.pk/index.php/jpmi/article/view/2849
547.Taher, Y., et al. MP48-11 Prospective randomized controlled study to assess the effect of perineal region cleansing with povidone iodine before transrectal needle biopsy of the prostate on infectious complications. Urology 84, S306
https://www.auajournals.org/doi/full/10.1016/j.juro.2015.02.1685
548.Yu, L., et al. Impact of insertion timing of iodophor cotton ball on the control of infection complications after transrectal ultrasound guided prostate biopsy. Nat Med J China, 2014. 94: 609.
https://pubmed.ncbi.nlm.nih.gov/24762693/
549.Ezenwa, E.V., et al. Apical peri-prostatic nerve block versus intra-rectal xylocaine gel for trans- rectal ultrasound guided prostate biopsy among Nigerian patients: A prospective randomized study. Niger J Clin Pract, 2020.
23: 1183.
https://pubmed.ncbi.nlm.nih.gov/32913154/
550.Pilatz, A., et al. Antibiotic prophylaxis for the prevention of infectious complications following prostate biopsy:
A Systematic Review and Meta-analysis. J Urol, 2020. 204: 224.
https://pubmed.ncbi.nlm.nih.gov/32105195/
551.Carignan, A., et al. Effectiveness of fosfomycin tromethamine prophylaxis in preventing infection following transrectal ultrasound-guided prostate needle biopsy: Results from a large Canadian cohort. J Glob Antimicrob Resist, 2019. 17: 112.
https://pubmed.ncbi.nlm.nih.gov/30553114/
552.Pilatz, A., et al. European Association of Urology Position Paper on the Prevention of Infectious Complications Following Prostate Biopsy. Eur Urol, 2020.